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CYTOCHROME P450S AND USES THEREOF 
RELATED APPLICATIONS 
This application is a continuation of co-pending U.S. 
patent application Ser. No. 14/243,778, filed Apr. 2, 2014, 
which is a continuation of U.S. patent application Ser. No. 
13/986,446, filed May 3, 2013 (now issued U.S. Pat. No. 
8,722,363), which is a continuation of U.S. patent applica-
tion Ser. No. 13/199,349, filed Aug. 26, 2011 (now issued 
U.S. Pat. No. 8,445,231), which is a continuation of U.S. 
patent application Ser. No. 12/182,000, filed Jul. 29, 2008 
(now issued U.S. Pat. No. 8,263,362), which is a continu-
ation of U.S. patent application Ser. No. 10/097,559, filed 
Mar. 8, 2002 (now issued U.S. Pat. No. 7,405,057), which 
claims the benefit of U.S. Provisional Application Nos. 
60/274,421 and 60/275,597, filed on Mar. 9, 2001 and Mar. 
13, 2001, respectively, all of which are hereby incorporated 
by reference. 
INCORPORATION BY REFERENCE OF 
SEQUENCE LISTING PROVIDED 
ELECTRONICALLY 
2 
green pepper (Hoshino et al., Phytochemistry 38:609-613, 
1995) have suggested that the oxidation of 5-epi-aristo-
lochene to capsidiol occurs in a two step process with one of 
the hydroxylation steps being constitutive and the other 
5 being mediated by an elicitor-inducible cytochrome P450 
(FIG. 1). Because 1-deoxycapsidiol had been isolated from 
natural sources (Watson et al., Biochem. Soc. Trans. 11:589, 
1983), Whitehead et al. (Phytochemistry 28:775-779, 1989), 
surmised that perhaps the biosynthesis of this intermediate 
10 was due to pathogen induction of a corresponding hydroxy-
lase. They therefore prepared synthetic 1-deoxycapsidiol 
and reported a modest conversion of this compound to 
capsidiol when fed to control or unelicited tobacco cell 
cultures. This was further supported by their observation that 
15 radiolabeled 5-epi-aristolochene was only converted to cap-
sidiol when fed to elicitor-induced cell cultures but not 
control cultures. Whitehead et al. (Phytochemistry 28:775-
779, 1989) therefore concluded that the 3-hydroxylase, 
responsible for hydroxylation of 5-epi-aristolochene at C3 to 
20 generate 1-deoxycapsidiol, was pathogen/elicitor inducible, 
while the 1-hydroxylase, responsible for hydroxylating 
1-deoxycapsidiol at the Cl to generate capsidiol, was con-
stitutive. Hoshino et al. (Phytochemistry 38:609-613, 1995) 
An electronic version of the Sequence Listing is filed 25 
herewith, the contents of which are incorporated by refer-
ence in their entirety. The electronic file was created on Apr. 
added to the observations of Whitehead et al. (Phytochem-
istry 28:775-779, 1989) by directly measuring 3-hydroxy-
lase-activity in microsomal preparations of arachidonic 
acid-elicited Capsicum annuum fruits and seedlings. These 
assays consisted of incubating 5-epi-aristolochene with 
microsome preparations and subsequently determining the 
1, 2014, is 65 kilobytes in size, and titled 207ESEQ001.txt. 
FIELD OF THE INVENTION 
This invention relates to cytochrome P450s and uses 
thereof. 
BACKGROUND OF THE INVENTION 
Cytochrome P450s encompass a superfamily of oxidases 
responsible for the oxidation of numerous endobiotics and 
thousands ofxenobiotics. In addition, in plants, cytochrome 
P450s play important roles in wound healing, pest resis-
tance, signaling, and anti-microbial and anti-fungal activity. 
Capsidiol is a bicyclic, dihydroxylated sesquiterpene pro-
duced by many Solanaceous species in response to a variety 
30 amount of 1-deoxycapsidiol generated by a combination of 
thin-layer chromatography (TLC) separations and gas chro-
matography (GC). Their evidence demonstrated that the 
conversion of 5-epi-aristolochene to 1-deoxycapsidiol was 
dependent on both NADPH and 0 2 , and that l-deoxycap-
35 sidiol accumulation in vitro was arrested by the P450 
antagonists carbon monoxide (Omura and Sato, J. Biol. 
Chern. 239:2370-2378, 1964), ancymidol (Coolbaugh et al., 
Plant Physiol. 62:571-576, 1978), and ketoconazole 
(Rademacher, Annu. Rev. Plant Physiol. Plant Mo!. Biol. 
40 51:501-531, 2000). 
Recent results suggest that the hydroxylation of 5-epi-
aristolochene is an important regulated step in capsidiol 
biosynthesis. In studies to evaluate the effectiveness of 
methyl-jasmonate as an inducer of capsidiol biosynthesis in 
45 tobacco cell cultures, Mandujano-Chavez et al. (Arch. Bio-
chem. Biophys. 381 :285-294, 2000), reported that the mod-
est accumulation of this phytoalexin was accompanied by a 
strong induction of EAS. This result implied that steps 
before or after the sesquiterpene cyclase reaction were 
of environmental stimuli, including exposure to UV (Back et 
al., Plant Cell. Physiol. 389:899-904, 1998) and infection by 
microorganisms (Molot et al., Physiol. Plant Pathol. 379-
389, 1981; Stolle et al., Phytopathology 78:1193-1197, 
1988; Keller et al., Planta. 205:467-476, 1998). It is the 
primary antibiotic or phytoalexin produced in tobacco in 
response to fungal elicitation, and it is derived from the 
isoprenoid pathway via its hydrocarbon precursor, 5-epi-
aristolochene (FIG. 1). Several of the biosynthetic enzymes 
leading up to 5-epi-aristolochene formation have been stud-
ied (Chappell, Annu. Rev. Plant Physiol. Plant Mo!. Biol. 
46:521-547, 1995), especially 5-epi-aristolochene synthase 
(BAS) (Vogeli and Chappell, Plant Physiol. 88: 1291-1296, 
1988; Back and Chappell, Proc. Natl. Acad. Sci. U.S.A. 
93:6841-6845, 1996; Mathis et al., Biochemistry 36:8340-
8348, 1997; Starks et al., Science 277: 1815-1820, 1997). 
BAS commits carbon to sesquiterpene metabolism by cata- 60 
lyzing the cyclization of farnesyl diphosphate (FPP) to 
5-epi-aristolochene. However, until the present invention, 
the enzyme(s) responsible for the conversion of 5-epi-
aristolochene to capsidiol has yet to be fully identified and 
characterized. 
50 limiting. Using an in vivo assay measuring the conversion 
rate of radiolabeled 5-epi-aristolochene to capsidiol, a very 
limited induction of the hydroxy lase activity was observed 
in cells treated with methyl jasmonate relative to that in 
fungal elicitor-treated cells. This result pointed to the 
55 hydroxylase reactions as a potentially limiting step in cap-
sidiol biosynthesis. 
SUMMARY OF THE INVENTION 
In one aspect, the invention features several isolated 
cytochrome P450 polypeptides (such as CYP71D20, 
CYP71D21, CYP73A27, CYP73A28, and CYP92A5, and 
P450s having substantial identity to these polypeptides), as 
well as isolated nucleic acid molecules that encode these 
65 P450s. 
Biochemical evidence from previous studies in tobacco 
(Whitehead et al., Phytochemistry 28:775-779, 1989) and 
In related aspects, the invention features a vector (such as 
an expression vector) including an isolated nucleic acid 
US 10,184,118 B2 
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molecule of the invention and a cell (for example, a pro-
karyotic cell, such as Agrobacterium or E. coli, or a eukary-
otic cell, such as a mammalian, insect, yeast, or plant cell) 
including the isolated nucleic acid molecule or vector. 
4 
In yet another aspect, the invention features an isoprenoid 
compound produced according to the above-mentioned 
methods. 
By "P450 polypeptide," "cytochrome P450," or "P450" is 
meant a polypeptide that contains a heme-binding domain 
and shows a CO absorption spectra peak at 450 nm accord-
ing to standard methods, for example, those described 
herein. Such P450s may also include, without limitation, 
hydroxylase activity, dual hydroxylase activity, demethylase 
In yet another aspect, the invention features a transgenic 
plant or transgenic plant component including a nucleic acid 
molecule of the invention, wherein the nucleic acid mol-
ecule is expressed in the transgenic plant or the transgenic 
plant component. Preferably, the transgenic plant or trans-
genic plant component is an angiosperm (for example, a 
monocot or dicot). In preferred embodiments, the transgenic 
plant or transgenic plant component is a solanaceous, maize, 
rice, or cruciferous plant or a component thereof. The 
invention further includes a seed produced by the transgenic 
plant or transgenic plant component, or progeny thereof. 
10 activity, or oxidase activity. Such enzymatic activities are 
determined using methods well known in the art. 
15 
By "polypeptide" is meant any chain of amino acids, 
regardless of length or post-translational modification (for 
example, glycosylation or phosphorylation). 
By "substantially identical" is meant a polypeptide or 
nucleic acid exhibiting at least 80 or 85%, preferably 90%, 
more preferably 95%, and most preferably 97%, or even 
98% identity to a reference amino acid sequence (for 
example, the amino acid sequence shown in SEQ ID NOS: 
In another aspect, the invention features a method of 
providing an increased level of resistance against a disease 
caused by a plant pathogen in a transgenic plant. The method 
involves: (a) producing a transgenic plant cell including the 
nucleic acid molecule of the invention integrated into the 
genome of the transgenic plant cell and positioned for 
expression in the plant cell; and (b) growing a transgenic 
plant from the plant cell wherein the nucleic acid molecule 
is expressed in the transgenic plant and the transgenic plant 
is thereby provided with an increased level of resistance 
against a disease caused by a plant pathogen. 
20 1, 3, 5, 7 and 11) or nucleic acid sequence (for example, the 
nucleic acid sequences shown in SEQ ID NOS:2, 4, 6, 8 and 
12, respectively). For polypeptides, the length of compari-
son sequences will generally be at least 16 amino acids, 
preferably at least 20 amino acids, more preferably at least 
25 25 amino acids, and most preferably 35 amino acids. For 
nucleic acids, the length of comparison sequences will 
generally be at least 50 nucleotides, preferably at least 60 
nucleotides, more preferably at least 75 nucleotides, and 
In another aspect, the invention features a method for 
producing an altered compound, the method including the 
steps of contacting the compound with one or more of the 
isolated polypeptides disclosed herein under conditions 30 
allowing for the hydroxylation, oxidation, demethylation, or 
methylation of the compound and recovering the altered 
compound. 
most preferably 110 nucleotides. 
Sequence identity is typically measured using sequence 
analysis software (for example, Sequence Analysis Software 
Package of the Genetics Computer Group, University of 
Wisconsin Biotechnology Center, 1710 University Avenue, 
Madison, Wis. 53705, BLAST, or PILEUP/PRETTYBOX In still another aspect, the invention features a hydroxy-
lating agent including any of the isolated polypeptides 
disclosed herein. 
In yet another embodiment, the invention features an 
isolated nucleic acid molecule that specifically hybridizes 
under highly stringent conditions to the complement of any 
one of the sequences described in SEQ ID N0:2 
(CYP71D20), SEQ ID N0:4 (CYP71D21), SEQ ID N0:6 
(CYP73A27), SEQ ID N0:8 (CYP73A28), or SEQ ID 
NO: 12 (CYP92A5), wherein such a nucleic acid molecule 
encodes a cytochrome P450 polypeptide. 
35 programs). Such software matches identical or similar 
sequences by assigning degrees of homology to various 
substitutions, deletions, and/or other modifications. Conser-
vative substitutions typically include substitutions within the 
following groups: glycine, alanine; valine, isoleucine, leu-
40 cine; aspartic acid, glutamic acid, asparagine, glutamine; 
serine, threonine; lysine, arginine; and phenylalanine, tyro-
In another aspect, the invention features a host cell 45 
expressing a recombinant isoprenoid synthase and a recom-
binant cytochrome P450. In preferred embodiments, the host 
cell further expresses, independently or in combination, a 
recombinant acetyltransferase, methyltransferase, or fatty 
acyltransferase. In other preferred embodiments, the host 50 
expresses an endogenous or recombinant cytochrome reduc-
tase. Preferably, the host cell is a yeast cell, a bacterial cell, 
an insect cell, or a plant cell. 
In a related aspect, the invention features a method for 
producing an isoprenoid compound, the method including 55 
the steps of: (a) culturing a cell that expresses a recombinant 
isoprenoid synthase and a recombinant cytochrome P450 
under conditions wherein the isoprenoid synthase and the 
cytochrome P450 are expressed and catalyze the formation 
of an isoprenoid compound not normally produced by the 60 
cell; and (b) recovering the isoprenoid compound. In pre-
ferred embodiments, the host cell further expresses a recom-
binant acetyltransferase, a recombinant methyltransferase, 
or a recombinant fatty acyltransferase. In other preferred 
embodiments, the host cell expresses an endogenous or 65 
recombinant cytochrome reductase. Preferably, the host cell 
is a yeast cell, a bacterial cell, an insect cell, or a plant cell. 
sme. 
By an "isolated polypeptide" is meant a P450 polypeptide 
(for example, a CYP71D20 (SEQ ID N0:1), CYP71D21 
(SEQ ID N0:3), CYP73A27 (SEQ ID N0:5), CYP73A28 
(SEQ ID N0:7), or CYP92A5 (SEQ ID N0:11) polypep-
tide) that has been separated from components that naturally 
accompany it. Typically, the polypeptide is isolated when it 
is at least 60%, by weight, free from the proteins and 
naturally-occurring organic molecules with which it is natu-
rally associated. Preferably, the preparation is at least 75%, 
more preferably at least 90%, and most preferably at least 
99%, by weight, a P450 polypeptide. An isolated P450 
polypeptide may be obtained, for example, by extraction 
from a natural source (for example, a plant cell); by expres-
sion of a recombinant nucleic acid encoding a P450 poly-
peptide; or by chemically synthesizing the protein. Purity 
can be measured by any appropriate method, for example, 
colurmi chromatography, polyacrylamide gel electrophore-
sis, or by HPLC analysis. 
By "derived from" or "obtained from" is meant isolated 
from or having the sequence of a naturally-occurring 
sequence (e.g., cDNA, genomic DNA, synthetic, or combi-
nation thereof). 
By "isolated nucleic acid molecule" is meant a nucleic 
acid molecule, e.g., a DNA molecule, that is free of the 
nucleic acid sequence(s) which, in the naturally-occurring 
US 10,184,118 B2 
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genome of the organism from which the nucleic acid mol-
ecule of the invention is derived, flank the nucleic acid 
molecule. The term therefore includes, for example, a 
recombinant DNA that is incorporated into a vector; into an 
autonomously replicating plasmid or virus; or into the 
genomic DNA of a prokaryote or eukaryote; or that exists as 
a separate molecule (for example, a cDNA or a genomic or 
cDNA fragment produced by PCR or restriction endonu-
clease digestion) independent of other sequences. The term 
"isolated nucleic acid molecule" also includes a recombinant 10 
DNA which is part of a hybrid gene encoding additional 
polypeptide sequences. 
By "specifically hybridizes" is meant that a nucleic acid 
sequence is capable of hybridizing to a DNA sequence at 
least under low stringency conditions, and preferably under 15 
high stringency conditions. For example, high stringency 
conditions may include hybridization at approximately 42° 
C. in about 50% formamide, 0.1 mg/mL sheared salmon 
sperm DNA, 1 % SDS, 2xSSC, 10% Dextran sulfate, a first 
wash at approximately 65° C. in about 2xSSC, 1 % SDS, 20 
followed by a second wash at approximately 65° C. in about 
O.lxSSC. Alternatively high stringency conditions may 
include hybridization at approximately 42° C. in about 50% 
formamide, 0.1 mg/mL sheared salmon sperm DNA, 0.5% 
SDS, 5xSSPE, lxDenhardt's, followed by two washes at 25 
room temperature in 2xSSC, 0.1 % SDS, and two washes at 
between 55-60° C. in 0.2xSSC, 0.1 % SDS. Reducing the 
stringency of the hybridization conditions may involve 
lowering the wash temperature and/or washing at a higher 
concentration of salt. For example, low stringency condi- 30 
tions may include washing in 2xSSC, 0.1 % SDS at 40° C. 
By "transformed cell" is meant a cell into which ( or into 
6 
suspension cultures, embryos, meristematic regions, callus 
tissue, leaves, roots, shoots, gametophytes, sporophytes, 
pollen, and microspores. 
By "plant component" is meant a part, segment, or organ 
obtained from an intact plant or plant cell. Exemplary plant 
components include, without limitation, somatic embryos, 
leaves, stems, roots, flowers, tendrils, fruits, scions, and 
rootstocks. 
By "transgene" is meant any piece of DNA which is 
inserted by artifice into a cell and typically becomes part of 
the genome, for example, the nuclear or plastidic genome, of 
the organism which develops from that cell. Such a trans-
gene may include a gene which is partly or entirely heter-
ologous (i.e., foreign) to the transgenic organism, or may 
represent a gene homologous to an endogenous gene of the 
organism. 
By "transgenic" is meant any cell which includes a DNA 
sequence which is inserted by artifice into a cell and 
becomes part of the genome of the organism which develops 
from that cell. As used herein, the transgenic organisms arc 
generally transgenic plants and the DNA (transgene) is 
inserted by artifice into the nuclear or plastidic genome. A 
transgenic plant according to the invention may contain one 
or more engineered traits. 
By "pathogen" is meant an organism whose infection of 
viable plant tissue elicits a disease response in the plant 
tissue. Such pathogens include, without limitation, bacteria, 
mycoplasmas, fungi, insects, nematodes, viruses, and 
viroids. Plant diseases caused by these pathogens are 
described in Chapters 11-16 of Agrios, Plant Pathology, 3rd 
ed., Academic Press, Inc., New York, 1988. 
By "increased level of resistance" is meant a greater level 
of resistance to a disease-causing pathogen in a transgenic 
an ancestor of which) has been introduced, by means of 
recombinant DNA techniques, a DNA molecule encoding 
(as used herein) a P450 polypeptide. 
By "positioned for expression" is meant that the DNA 
molecule is positioned adjacent to a DNA sequence which 
directs transcription and translation of the sequence (i.e., 
facilitates the production of, for example, a P450 polypep-
tide, a recombinant protein, or an RNA molecule). 
35 plant ( or cell or seed thereof) of the invention than the level 
of resistance relative to a control plant (for example, a 
non-transgenic plant). In preferred embodiments, the level 
of resistance in a transgenic plant of the invention is at least 
20% (and preferably 30% or 40%) greater than the resis-
By "reporter gene" is meant a gene whose expression may 
40 tance of a control plant. In other preferred embodiments, the 
level of resistance to a disease-causing pathogen is 50% 
greater, 60% greater, and more preferably even 75% or 90% 
greater than a control plant; with up to 100% above the level 
be assayed; such genes include, without limitation, beta-
glucuronidase (GUS), luciferase, chloramphenicol 
transacetylase (CAT), green fluorescent protein (GFP), beta-
galactosidase, herbicide resistant genes, and antibiotic resis- 45 
tance genes. 
By "expression control region" is meant any minimal 
sequence sufficient to direct transcription. Included in the 
invention are promoter elements that are sufficient to render 
promoter-dependent gene expression controllable for cell-, 50 
tissue-, or organ-specific gene expression, or elements that 
are inducible by external signals or agents (for example, 
light-, pathogen-, wound-, stress-, or hormone-inducible 
elements or chemical inducers such as salicylic acid (SA) or 
2,2-dichloro isonicotinic acid (INA)); such elements may be 55 
located in the 5' or 3' regions of the native gene or engi-
neered into a transgene construct. 
By "operably linked" is meant that a gene and a regulatory 
sequence( s) are connected in such a way as to permit gene 
expression when the appropriate molecules (for example, 60 
transcriptional activator proteins) are bound to the regula-
tory sequence(s). 
By "plant cell" is meant any self-propagating cell 
bounded by a semi-permeable membrane and typically is 
one containing a plastid. Such a cell also requires a cell wall 65 
if further propagation is desired. Plant cell, as used herein 
includes, without limitation, algae, cyanobacteria, seeds, 
of resistance as compared to a control plant being most 
preferred. The level ofresistance is measured using conven-
tional methods. For example, the level of resistance to a 
pathogen may be determined by comparing physical features 
and characteristics (for example, plant height and weight, or 
by comparing disease symptoms, for example, delayed 
lesion development, reduced lesion size, leaf wilting and 
curling, water-soaked spots, and discoloration of cells) of 
transgenic plants. 
By "purified antibody" is meant antibody which is at least 
60%, by weight, free from proteins and naturally-occurring 
organic molecules with which it is naturally associated. 
Preferably, the preparation is at least 75%, more preferably 
90%, and most preferably at least 99%, by weight, antibody, 
for example, an acquired resistance polypeptide-specific 
antibody. A purified P450 antibody may be obtained, for 
example, by affinity chromatography using a recombinantly-
produced P450 polypeptide and standard techniques. 
By "specifically binds" is meant an antibody which rec-
ognizes and binds a P450 protein but which does not 
substantially recognize and bind other molecules in a 
sample, for example, a biological sample, which naturally 
includes a P450 protein such as CYP71D20, CYP71D21, 
CYP73A27, CYP73A28, or CYP92A5. 
US 10,184,118 B2 
7 
Other features and advantages of the invention will be 
apparent from the following description of the preferred 
embodiments thereof, and from the claims. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a schematic diagram of a proposed alternative 
pathway for the biosynthesis of capsidiol in elicitor-treated 
Nicotiana tabacum cells. 5-epi-aristolochene is synthesized 
from FPP by the action of a sesquiterpene cyclase, 5-epi-
aristolochene synthase (EAS), and is subsequently hydroxy-
lated at Cl and C3 to form capsidiol. 
FIG. 2 is a graph showing an induction time course for 
sesquiterpene cyclase enzyme activity and sesquiterpene 
hydroxylase activity in cellulase-treated cell cultures. Ses-
quiterpene cyclase (5-epi-aristolochene synthase, EAS) 
enzyme activity was determined in extracts prepared from 
control ( open squares) and elicitor-treated ( closed squares) 
cells collected at the indicated time points. Sesquiterpene 
hydroxylase activity was determined using an indirect assay 
for control ( open circles) and elicitor-treated ( closed circles) 
cells. Cell cultures were incubated with [3 H]-5-epi-aristo-
lochene for 3 hours ending at the indicated time points 
before quantifying the incorporation of radioactivity into 
extracellular capsidiol, a dihydroxylated form of aristo-
lochene (Mandujano-Chavez et al., Arch. Biochem. Bio-
phys. 381:285-294, 2000). 
FIGS. 3A-3B are a series of graphs showing the dose 
dependent inhibition of 5-epi-aristolochene hydroxylase 
activity by ancymidol and ketoconazole. Cell cultures were 
incubated in the presence of cellulase (0.5 µg/mL) plus the 
indicated concentrations of ancymidol (A) or ketoconazole 
(B) for 12 hours prior to measuring the in vivo 5-epi-
aristolochene hydroxylase activity in the cell suspension 
cultures (squares), or the EAS enzyme activity in extracts 
prepared from the collected cells (triangles). The in vitro 
activity of a purified EAS preparation (Back and Chappell, 
J. Biol. Chem. 270:7375-7381, 1995) was also measured at 
the indicated inhibitor concentrations as an additional test 
for non-specific effects of these inhibitors (circles). 
FIG. 4A is a schematic diagram of the primary structure 
of a generalized cytochrome P450 with conserved domains 
used for the design of PCR primers highlighted (SEQ ID 
NOS:26-29). 
8 
tion isolated from yeast expressing the CYP92A5 (A) and 
CYP71D20 (B) cDNAs. Expression of the respective plas-
mid constructs engineered into the yeast (WATll) cells was 
induced by a galactose treatment, followed by isolation of 
5 microsomal preparations. The difference adsorption spectra 
of microsomes incubated in the presence (solid lines) and 
absence (broken lines) of carbon monoxide was determined. 
FIGS. 7A-7D are a series of gas chromatograms of the 
reaction products formed upon incubation of microsomes 
10 isolated from WATll yeast cells containing the CYP71D20 
expression construct (A and C) or vector control DNA (B 
and D) with sesquiterpene substrates. Microsomes isolated 
from the indicated yeast lines were incubated with 5-epi-
aristolochene (A and B) or 1-deoxycapsidiol (C and D) in the 
15 presence (solid lines) or absence (dashed lines) ofNADPH. 
The identities of 5-epi-aristolochene, 1-deoxycapsidiol, and 
capsidiol were verified by mass spectrometry. 
FIGS. SA-SD provide a sequence comparison of the 
amino acid sequence of Nicotiana tabacum 5-epi-aristo-
20 !achene (sesquiterpene) hydroxyl ase NtCYP71D20 (SEQ 
ID N0:1) with other plant terpene hydroxylases (SEQ ID 
NOS:39-43). NrCYP71A5vl (GenBank accession number 
CAA70575) catalyzes the mono-hydroxylation ofnerol and 
geraniol, linear monoterpenes, while PaCYP71Al (A35867) 
25 catalyzes the epoxidation of these substrates (Hallahan et al., 
Biochim. Biophys. Acta. 1201:94-100, 1994). 
MsCYP71D18 (AAD44150) and MpCYP71D13 
(AAD44151) catalyze the mono-hydroxylation at C6 and C3 
of limonene, a cyclic monoterpene, respectively (Lupien et 
30 al., Arch. Biochem. Biophys. 368:181-192, 1999). 
AtCYP701A3 (AAC39505) encodes for kaurene oxidase, 
which catalyzes a 3-step reaction including a hydroxylation 
followed by oxidation of a diterpene (Helliwell et al., Plant 
Physiol. 119:507-510, 1999). Shown are sequences from 
35 Mentha piperita (MpCYP71D13; SEQ ID N0:39), Mentha 
spicata (MsCYP71D18; SEQ ID N0:40), Nepeta racemosa 
(NrCYP71A5vl; SEQ ID N0:41), Nicotiana tabacum 
(NtCYP71D20; SEQ ID N0:1), Persea americana 
(PaCYP71Al; SEQ ID N0:42), and Arabidopsis thaliana 
40 (CYP701A3; SEQ ID N0:43). Conserved residues are 
shaded. 
DETAILED DESCRIPTION 
FIG. 48 is a list of the degenerate P450-specific primers 45 
(SEQ ID NOS:30-36) that were used in various combina-
tions with vector specific primers in the amplification of 
cytochrome P450 cDNA fragments. 
Capsidiol is a bicyclic, dihydroxylated sesquiterpene pro-
duced by several Solanaceous species in response to a 
variety of environmental stimuli. It is the primary antimi-
crobial compound produced by Nicotiana tabacum in 
response to fungal elicitation, and it is formed via the 
isoprenoid pathway from 5-epi-aristolochene. Much of the 
biosynthetic pathway for the formation of this compound 
FIG. 4C is a scanned image of an ethidium bromide-
stained agarose gel showing the PCR products amplified 50 
from a directional cDNA library prepared with mRNA 
isolated from elicitor-treated cells using the degenerate 
primer GRRXCP(A/G)- for (SEQ ID N0:35) and the T7 
vector-specific primer (SEQ ID N0:37). The T3 vector-
specific primer is also shown (SEQ ID N0:38). 55 
has been elucidated, except for the enzyme(s) responsible 
for the conversion of the allylic sesquiterpene 5-epi-aristo-
lochene to its dihydroxylated form, capsidiol. 
Accordingly, an in vivo assay for 5-epi-aristolochene 
hydroxylase-activity was developed and used to demon-
strate a dose dependent inhibition of activity by ancymidol 
and ketoconazole, two well-characterized inhibitors of 
cytochrome P450 enzymes. Using degenerate oligonucle-
otide primers designed to the well-conserved domains found 
within most P450 enzymes, including the heme binding 
domain, cDNA fragments representing four distinct P450 
families (CYP71, CYP73, CYP82, and CYP92) were ampli-
fied from a cDNA library prepared against mRNA from 
FIG. 5 is a series of Northern blots showing the induction 
time course for CYP71D, CYP73A, CYP82E, CYP92A, and 
EAS transcript accumulation in elicitor treated cells. Total 
RNA was extracted from tobacco suspension cells incubated 
with the cellulase elicitor for the indicated durations, size 60 
fractionated by agarose gel electrophoresis under denaturing 
conditions, and transferred to a nylon membrane before 
probing with the respective full-length cDNAs. The unifor-
mity of sample loading was verified by ethidium bromide 
staining of ribosomal RNA (Loading control). 65 elicitor-treated cells using PCR. The PCR fragments were 
subsequently used to isolate full-length cDNAs (CYP71D20 
(SEQ ID N0:2) and D21 (SEQ ID N0:4), CYP73A27 (SEQ 
FIGS. 6A-6B are a series of graphs showing carbon 
monoxide (CO) difference spectra of the microsomal frac-
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ID N0:6) and A28 (SEQ ID N0:8), CYP82El (SEQ ID 
N0:10), and CYP92A5 (SEQ ID N0:12)), and these in turn 
were used to demonstrate that the corresponding mRNAs 
were all induced in elicitor-treated cells, albeit with different 
induction patterns. 
EXAMPLES 
There now follows a description of the cloning of several 
P450s from Nicotiana tabacum. These examples are pro-
vided for the purpose of illustrating the invention, and are 
not to be considered as limiting. 
Inhibition of the 5-epi-aristolochene to Capsidiol Conver-
sion by P450 Antagonists 
Using an indirect assay, a detailed induction time course 
of 5EAH activity in elicitor-induced cell cultures was deter-
mined relative to that of EAS activity (FIG. 2), the well-
characterized sesquiterpene cyclase activity that catalyzes 
the formation of 5-epi-aristolochene from FPP (FIG. 1). 
Using assays for EAS and 5EAH, EAS activity is not 
detectable in control cell cultures, but is induced signifi-
cantly within 3 hours and reaches its maximal level within 
15 to 18 hours of elicitor-treatment. Similar to the EAS 
enzyme activity, 5EAH activity was negligible in control 
cell cultures. Nonetheless, after an apparent lag phase of 8 
hours, a rapid induction of hydroxylase activity was 
observed 10 to 15 hours post elicitor addition to the cell 
cultures, reaching a maximum by 18 hours followed by a 
rather gradual decline of 10 to 20% over the next 8 hours. 
Tobacco cell suspension cultures treated with cellulase 
plus varying concentrations of ancymidol or ketoconazole 
were pre-incubated for 12 hours before measuring the cells' 
ability to convert exogenous supplied [3 H] labeled 5-epi-
aristolochene to radiolabeled capsidiol during a subsequent 
10 
database searches, and these corresponded to typical plant 
P450 family members of the CYP71, CYP73, CYP92 and 
CYP82 classes. Each of these PCR fragments was isolated 
multiple times in separate experiments. In addition, we 
5 isolated full-length cDNAs for these P450 family members. 
Table 1 compares the similarity and identity of the full-
length cDNAs of P450 family members with those of their 
nearest family member in the GenBank database. In addi-
tion, FIGS. SA-SD shows an amino acid alignment of 
10 several terpene cytochrome P450s. Alignments were per-
formed using the algorithm of the MACVECTOR software 
suite. 
TABLE 1 
15 
Full-length cDNAs cloned from an elicited cDNA libr!!!]'. 
Cytochrome P450 Nearest relative/ 
cDNA clone accession nwnber % Identity % Similarity 
20 CYP71D20 CYP71D7 (S. chacoense) 76.5 88.8 
Gen EMBL U48435 
CYP71D21 CYP71D7 (S chacoense) 76.3 88.8 
Gen EMBL U48435 
CYP73A27 CYP73A15 (P. vulgaris) 79.4 92.6 
Gen EMBL Y09447 
25 CYP73A28 CYP73A15 (P. vulgaris) 79.2 92.4 Gen EMBL Y09447 
CYP82El CYP82El (N. tabacum) 100.0 100.0 
Gen EMBL AB015762 
CYP92A5 CYP92A3 (N. tabacum) 95.5 98.6 
Gen EMBL X96784 
30 
3 hour incubation period (FIGS. 3A-3B). Apparent activity 35 
of 5EAH was inhibited in a dose-dependent manner with 
approximately 50% inhibition by either 25 µM ancymidol or 
ketoconazole, and more than 80% by 75 µM ancymidol and 
95% by 100 µM ketoconazole (FIGS. 3A and 38). Impor-
tantly, neither the in vitro activity of recombinant EAS nor 40 
the induction ofEAS in the elicitor-treated cell cultures was 
significantly affected by ancymidol at concentrations as high 
The cloned fragments were used in a second step to isolate 
full-length clones from the cDNA library. Screening the 
cDNA library by hybridization with the CYP71 and CYP73 
gene fragments yielded four full-length cDNAs, two 
CYP71Ds and two CYP73As. The former clones were 
designated CYP71D20 and CYP71D21, and the latter were 
designated CYP73A27 and CYP73A28. The other two 
cDNA fragments corresponded to tobacco cDNAs already 
found in the GenBank database, CYP82El and CYP92A3. 
These two cDNAs were cloned using specific primers 
designed with the help of the available sequence information 
to amplify the full-length cDNA. 
as 100 µM (FIG. 3A). Ketoconazole also does not appear to 
affect the in vitro activity ofEAS. However, the inducibility 
Induction of Cytochrome P450 mRNAs in Elicitor-treated 
Cells 
To correlate a biochemical role for P450s in sesquiterpene 
metabolism, RNA blot analyses were used to determine the 
steady-state levels of the mRNAs coding for all four of the 
cytochrome P450 clones and EAS in control and elicitor-
treated cells (FIG. 5). The mRNAs for all four of the P450s 
of cyclase activity in elicitor-treated cell extracts was inhib- 45 
ited by ketoconazole at concentrations above 50 µM (FIG. 
38). Therefore, the specificity ofketoconazole as an inhibi-
tor of P450 type reactions should be assessed at or below a 
concentration of 50 µM under these experimental condi-
tions. 50 were rapidly and transiently induced with slightly different 
time courses relative to one another and to the EAS mRNA. 
CYP73A27 mRNA, for instance, displayed an induction 
pattern similar to that of EAS with the maximum mRNA 
level occurring 9 to 12 hours after elicitation. While the EAS 
Isolation of Elicitor-inducible Cytochrome P450 cDNAs 
A two-step approach for the isolation of candidate P450 
cDNAs was followed. A PCR strategy was first employed 
using a directional cDNA library prepared against mRNA 
isolated from elicitor-induced cells as the template and 
degenerate PCR primers (FIGS. 4A-4C). Sequence align-
ments of cytochrome P450s from multiple families across 
kingdoms were used to identify conserved regions to which 
a series of degenerate primers were prepared (FIGS. 4A and 
48). In cloning experiments, 450 to 550 bp products were 
expected from reactions utilizing the primer prepared to the 
heme-binding domain (GRRXCP(A/G)) (SEQ ID NOS:27 
and 28) and the T7 vector primer (FIG. 4C). The mixtures 
of reaction products were shotgun cloned, and approxi-
mately 100 of the cloned PCR fragments were sequenced. 
About half of the sequenced DNAs contained signature 
sequences typical of P450 enzymes as revealed by BlastX 
55 mRNA remained high throughout the duration of the experi-
ment, the CYP73A27 mRNA was negligible in cells 24 
hours after elicitor-treatment. In contrast, the CYP71D 
mRNA was more rapidly induced than the EAS mRNA, 
reached its maximum 6 to 9 hours after elicitation, and was 
60 declining by 12 hours when the EAS mRNA level was still 
very high. 
Functional Identification of CYP71D20 as 5-epi-aristo-
lochene Hydroxylase 
To ascribe functional identity to the various P450 cDNAs, 
65 full-length cDNAs for CYP71D20, CYP82El and 
CYP92A5 were inserted into the yeast expression vector 
pYeDP60 (Urban et al., Biochimie 72:463-472, 1990; Porn-
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pon et al., Methods Enzymol. 272:51-64, 1996) and the 
expression of each in WATll, a yeast line containing an 
integrated Arabidopsis thaliana cytochrome reductase gene 
(Pompon et al., Methods Enzymol. 272:51-64, 1996; Urban 
12 
Chemicals 
et al., J. Biol. Chem. 272:19176-19186, 1997), was deter- 5 
mined. Engineering the CYP73A27 cDNA required an extra 
modification because of an unusually long N-terminus with 
several hydrophilic residues that may interfere with proper 
intracellular targeting (Nedelkina et al., Plant Mo!. Biol. 
10 39:1079-1090, 1999). This unusual leader sequence there-
Standard laboratory reagents were purchased from Becton 
Dickinson Microbiology Systems (Sparks, Md.), FisherBio-
tech (Fair Lawn, N.J.) and Sigma Chemical Company (St. 
Louis, Mo.). 
Biological Materials and Induction Treatments 
Nicotiana tabacum cv. KY14 plants and cell suspension 
cultures were used. Cell suspension cultures were main-
tained in modified Murashige-Skoog (Vcigeli and Chappell, 
Plant Physiol. 88: 1291-1296, 1988). Cultures in their rapid 
phase of growth (3 days old) were used for all experiments. fore was replaced with the membrane anchoring sequence of 
CYP73Al, a cinnamate 4-hydroxylase previously demon-
strated to express well in yeast (Fahrendorf and Dixon, Arch. 
Biochem. Biophys. 305:509-515, 1993; Pompon et al., 15 
Methods Enzymol. 272:51-64, 1996). Expression of all 
these cDNAs was under the control of the glucose-repres-
sible, galactose-inducible GALlO-CYCl promoter (Guar-
ente et al., Proc. Natl. Acad. Sci. U.S.A. 79:7410-7414, 
1982), and expression was compared to yeast transformed 20 
with the parent pYeDP60 vector (control) alone. 
At the indicated times, cells were collected and separated 
from media by vacuum filtration and stored at -80° C. 
Induction treatments were performed by the addition of 
the fungal elicitors, cellulase (Trichoderma viride, Type RS, 
Onozuka) orparaciticein (O'Donohue et al., Plant Mo!. Biol. 
27:577-586, 1995) at the indicated concentrations. Paraciti-
cein was purified from E. coli cells overexpressing a recom-
binant paraciticein protein containing a carboxy-terminal 
histidine purification tag. 
In Vivo 5-epi-aristolochene Hydroxy lase Assay and Inhi-
bition Studies After induction with galactose for approximately 16 
hours, control cells and cells containing the various P450 
constructs were collected, and microsomes prepared from 
each were analyzed for general P450 expression by CO-
difference spectroscopy (Omura and Sato, J. Biol. Chem. 
239:2370-2378, 1964). Microsomes prepared from cells 
containing the CYP71D20 (FIG. 6A) and CYP92A5 (FIG. 
68) constructs both showed characteristic CO difference 
spectra with peaks at 450 nm, indicating that the encoded 
proteins were assembling properly with their heme cofactor. 
Using the extinction coefficient of 91 mM- 1·cm-1 for heme 
binding proteins (Omura and Sato, J. Biol. Chem. 239:2370-
23 78, 1964 ), it was determined that approximately 107 pmol 
of CYP71D20 and 268 pmol of CYP92A5 were expressed 
in the yeast cells per milligram of total yeast protein. 
Both 5-epi-aristolochene and 1-deoxycapsidiol were 
metabolized to only one product with the same retention 
time as capsidiol. Obvious by its absence, no reaction 
product having a retention time similar to deoxycapsidiol 
was detectable in the 5-epi-aristolochene incubations (FIGS. 
7 A-7D). Co-injection of authentic capsidiol with the respec-
tive reaction products resulted in a single GC peak having a 
16.2 minute retention time, identical to capsidiol. Mass 
spectra patterns for the separate reaction products were 
identical to that for the capsidiol standard (EIMS m/z 236, 
221, 203, 185, 175, 163, 157, 133, 121, 107, 93, 79, 67, 55, 
43, 41). 
The in vivo assay data presented in FIGS. 2 and 3A-3B of 
the current work indicate that the conversion of 5-epi-
aristolochene is catalyzed by at least one inducible 
cytochrome P450 mediated reaction. 
Furthermore, any of the cytochrome p450 polypeptides 
described herein may include one or more hydroxylase 
activities which can incorporate hydroxyl groups into at 
least two distant sites on an isoprenoid compound. The 
addition of these hydroxyl groups may occur, for example, 
sequentially, by adding a hydroxyl group first to one site and 
then the other, in either order. Moreover, such hydroxylases 
may be mutated to limit their ability to hydroxylate a 
substrate at only one site, or, alternatively, to provide ste-
reochemical specificity to their hydroxylating activity. 
The above-described experiments were performed using 
the following materials and methods. 
5-epi-aristolochene hydroxy lase-activity was measured as 
the incorporation of [3H]-5-epi-aristolochene into extracel-
25 lular capsidiol by intact cells. [3 H]-5-epi-aristolochene was 
produced by incubating an excess of [l-3 H] farnesyl diphos-
phate (1 µM, 20.5 Ci/mmol) with recombinant 5-epi-aristo-
lochene synthase (Back et al., Arch. Biochcm. Biophys. 
315:527-532, 1994; Rising et al., J. Am. Chem. Soc. 122: 
30 1861-1866, 2000). The hexane extractable radioactivity 
from reactions was treated with a small amount of silica to 
remove any farnesol or residual FPP before quantifying the 
yield of radioactive 5-epi-aristolochene by liquid scintilla-
tion counting. The hexane solvent was removed under a 
35 gentle stream of N2 gas, and the dried residue was re-
dissolved in acetone. Control and elicitor-treated cells were 
then incubated with [3H]-5-epi-aristolochene (approxi-
mately 100,000 dpm at 2.5 nM) for 3 hour periods at various 
points during an induction time course before collecting the 
40 cell and media samples. Detection and quantification of 
capsidiol in the extracellular culture media was performed as 
reported previously (Chappell et al., Phytochemistry 
26:2259-2260, 1987), and the amount of radioactivity incor-
porated into capsidiol was determined. For these determi-
45 nations, samples were separated by TLC, and the zones 
corresponding to capsidiol were scraped from the plate for 
scintillation counting. 
Inhibition studies were performed by the addition of the 
P450 inhibitors ancymidol (Coolbaugh et al., Plant Physiol. 
50 62:571-576, 1978; Hoshino et al., Phytochemistry 38:609-
613, 1995) and ketoconazole (Hoshino et al., Phytochemis-
try 38:609-613, 1995; Rademacher, Annu. Rev. Plant 
Physiol. Plant Mo!. Biol. 51:501-531, 2000) directly to the 
cell cultures or enzyme assay mix. Cell cultures were 
55 incubated in the presence of cellulase (0.5 µg/mL) and 
indicated concentrations of ancymidol or ketoconazole for 
12 hours prior to the addition of [3 H]-5-epi-aristolochene. 
After a further 3 hour incubation period, the cells and media 
were collected. The amount of radioactivity incorporated 
60 into extracellular capsidiol was determined as described 
above. To evaluate secondary effects of these inhibitors, the 
level of inducible sesquiterpene cyclase activity in the 
collected cells was determined according to Vogeli et al. 
(Plant Physiol. 93:182-187, 1990), as well as in vitro assays 
65 with purified recombinant EAS (Back et al., Arch. Biochem. 
Biophys. 315:527-532, 1994) incubated with the indicated 
concentrations of ancymidol and ketoconazole. 
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All experiments were replicated in several independent 
trials. While the absolute values presented may have varied 
between experiments by as much as 50%, the trends and 
time courses were consistent throughout. 
Construction of an Elicitor-induced cDNA Library 
Cell cultures were incubated with fungal elicitor (0.5 µg 
cellulase/mL) for 6 hours before collecting the cells by 
filtration. The cells were kept frozen at -80° C. until total 
RNA was extracted from them using Trizol (Life Technolo-
gies, Rockville, Md.) according to the manufacturer's 
instructions. Poly (At RNA was purified by two rounds of 
oligo (dT) cellulose colunm chromatography (Life Tech-
nologies, Rockville, Md.). cDNA synthesis and library con-
struction were subsequently carried out using the UNI-ZAP 
XR library kit (Stratagene, La Jolla, Calif.), according to 
manufacturer's instructions. 
PCR Cloning Strategy 
Cytochrome P450 cDNA fragments were amplified from 
the elicitor-induced cDNA library using various combina-
tions of degenerate forward and reverse primers with the 
vector-specific T3 and T7 primers. The template DNA was 
prepared from a 500 µL aliquot of the elicitor-induced 
cDNA library (3xl06 pfu/µL) by heat denaturation at 70° C. 
for 10 minutes, followed by phenol/chloroform extraction, 
ethanol precipitation and re-suspension in 500 µL of sterile, 
deionized water. Amplification reactions were performed in 
50 µL volumes containing 50 mM KC!; 10 mM Tris-HCI, pH 
8.8; 1.5 mM MgCl2 ; 200 µM of each dNTP; 2 µ!, template 
DNA; 20 pmol each of forward and reverse primer; and 1 
unit Taq Polymerase (Life Technologies, Rockville, Md.). 
Reactions were preheated at 94 ° C. for 2 minutes, followed 
by thirty-five cycles of denaturing at 94° C. for 1 minute, 
annealing at 50° C. for 1 minute 30 seconds, and polymer-
ization at 72° C. for 2 minutes. The reactions were com-
pleted by a IO-minute extension at 72° C. Aliquots of the 
reaction products were examined for DNA products by 
agarose gel fractionation, and ligated directly into the 
pGEM-T Easy vector (Promega, Madison, Wis.). Resulting 
recombinant plasmids containing insert DNAs within the 
expected size range were sequenced using T7 and Sp6 
primers. 
DNA Sequencing 
All the DNA sequencing reactions were performed using 
the BIGDYE™ Terminator Cycle sequencing kit (Perkin-
Elmer, Wellesley, Mass.) with the sequences being read on 
an automated ABI Prism 310 Genetic Analyzer (Applied 
Biosystems, Foster City, Calif.). Computer assessment of the 
DNA sequence information was performed using the 
MACVECTOR (Oxford Molecular, Madison, Wis.) soft-
ware package. 
cDNA Library Screening 
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manufacturer's instructions (Roche Molecular Biochemi-
cals, Indianapolis, Ind.). Plaques exhibiting strong hybrid-
ization were plaque purified, auto-subcloned to their plasmid 
forms according to the manufacturer's recommendations 
5 (Stratagene, La Jolla, Calif.), and then subjected to DNA 
sequencing as described above. 
RNA Analysis 
RNA gel blot analysis was carried out using 10 µg aliquots 
of total RNA. RNA samples were heat-denatured at 70° C. 
10 for 15 minutes in sample buffer (Ix MOPS, 50% formamide, 
16% formaldehyde, 30% glycerol, and 3% ethidium bro-
mide), and size fractionated on a 1.2% agarose gel contain-
ing lxMOPS and 18.1% formaldehyde. Uniformity of 
sample loading was determined by visual inspection of the 
15 gel for rRNA bands. The RNAs were then transferred to a 
Zeta Probe nylon membrane (Bio-Rad Laboratories, Hercu-
les, Calif.) and hybridized according to the manufacturer's 
recommendations. Full-length cDNA probes were labeled 
with [32P]-dCTP (PRIME-IT Kit, Stratagene, La Jolla, 
20 Calif.) prior to hybridization. After hybridization, the mem-
branes were washed in 2xSSC/0.1 % SDS once at room 
temperature followed by sequential washes in 0.2xSSC/ 
0.1 % SDS at 42° C. and 65° C. Hybridization was detected 
with a Phosphoimager (Molecular Dynamics, model 445 
25 SI). 
Construction of Yeast Expression Vectors 
The coding regions of the P450 cDNAs were cloned into 
the p Y cDP60 expression vector (Urban et al., J. Biol. Chem. 
272:19176-19186, 1990; Pompon et al., Methods Enzymol. 
30 272:51-64, 1996). Appropriate BamHI, EcoRI, and Sstl 
restriction sites (underlined) were introduced via PCR prim-
ers containing these sequences either upstream of the trans-
lation start site (ATG) or downstream of the stop codon 
(TAA or TGA). The primers used to amplify the CYP71D20 
35 cDNA were 5'-GGGGGATCCATGCAATTCTTCAGC 
TTGGTTTCC-3' (SEQ ID N0:17) and 5'-GGG 
GAATTCTTACTCTCGAGAAGGTTGATAAGG-3' (SEQ 
ID N0:18); for the CYP82El cDNA 5'-CCC 
GGATCCATGTATCATCTTCTTTCTCCC-3' (SEQ ID 
40 N0:19) and 5'-GGGGAATTCTCAATATTGATAAAGC 
GTAGGAGG-3' (SEQ ID N0:20); and for the CYP92A3 
cDNA 5'-CCCGGATCCATGCAATCCTTCAGCTT 
GGTTTCC-3' (SEQ ID N0:21) and 5'-GGG 
GAGCTCTCACTCGCAAGAAGATTGATAAGG-3' (SEQ 
45 ID NO: 22). Two long, overlapping (italicized) primers 
5'-GCCATTATCGGCGCAATACTAATCTCCAAACTC-
CGCGGTAAAAAATTCAAGCTCCCACCTGGTCCAA-
CAGCAGTC-3' (SEQ ID N0:23) and 5'-GGG 
GGATCCATGGACCTCCTCCTCATAGAAAAAACCCT 
50 CGTCGCCTTATTCGCCGCCATTATCGGCGCAATAC 
The cDNA library was screened with digoxigenin labeled 
probes. A 258 bp DNA fragment amplified from the pGEM-
deg6.4 clone using gene-specific forward (5'-GGCGGA-
GAATTTGTCCTGGAATGTCATTTGGTTTAG-3' (SEQ 55 
ID N0:13)) and reverse (5'-GTACAATAGTGAGGTT-
GACAATG-3' (SEQ ID N0:14)) primers; and a 374 bp 
DNA fragment amplified from the pBKS-CYPB3.843 clone 
with specific forward (5'-GGTGGTTGTGAATGCATG-3' 
(SEQ ID N0:15)) and reverse (5'-TTATGCAGCAATAG- 60 
GCTTGAAGACA-3' (SEQ ID N0:16)) primers, were used 
TA-3' (SEQ ID N0:24) coding for the N-terminal sequence 
of CYP73Al (GenEMBL Zl 7369) up to the hinge region 
were used for the modification of the membrane anchoring 
segment of CYP73A27 to avoid possible problems with 
intracellular targeting due to the unusual N-terminus (Nedel-
kina et al., 1999); the reverse primer used for both ampli-
fications was 5'-GGGGAGCTCTTATGCAGCAATA 
GGCTTGAAGAC-3' (SEQ ID N0:25). CYP71D20 and 
CYP73A27 were amplified using full-length cDNA tem-
plates, whereas CYP82El and CYP92A5 were amplified 
directly from the cDNA library template. Amplifications 
were performed in 50 µL reactions containing lxPfx ampli-
fication buffer; 1 mM MgSO 4 ; 300 µM of each dNTP; 10 ng 
template DNA; 20 pmol each of forward and reverse primer; 
and 1.25 units PLATINUM® Pfx Polymerase (Life Tech-
nologies, Rockville, Md.). Reactions were preheated at 94° 
C. for 2 minutes, followed by thirty-five cycles of denaturing 
to screen for CYP71Ds. The probes were labeled with 
digoxigenin-11-dUTP using the PCR DIG Labeling Mix 
(Roche Molecular Biochemicals, Indianapolis, Ind.), hybrid-
ized to plaque lifts of the cDNA library plated at approxi- 65 
mately 10,000 PFUs per 150 mm plate, and was hybridiza-
tion detected with the DIG detection system according to the 
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at 94° C. for 15 seconds, annealing at 55° C. for 30 seconds, 
and elongating at 68° C. for 1.5 minutes. PCR products were 
ligated into the pGEM-T EASY vector (Promega, Madison, 
Wis.) and subcloned into the pYcDP60 vector. The resulting 
constructs were validated by a combination of PCR and 5 
DNA sequencing. 
Yeast Expression Studies 
Verified pYeDP60-P450 cDNA constructs were intro-
duced into the yeast WATll line, a derivative of the W303-
1B strain (MATa; ade 2-1; his 3-11; leu 2-3,-112; ura 3-1; 10 
canR; cyr+), provided by Dr. P. Urban (Centre de Genetique 
Moleculaire, CNRS, Gif-sur-Yvette, France). The endog-
enous NADPH-cytochrome P450 reductase (CPRl) locus 
has been replaced withATRl, a NADPH-cytochrome P450 
reductase from Arabidopsis thaliana (Pompon et al., Meth- 15 
ods Enzymol. 272:51-64, 1996; Urban et al., J. Biol. Chem. 
272: 19176-19186, 1997), in the WATll line. Yeast was 
grown overnight in a 30° C. shaker in YPAD (1 g/1 yeast 
extract; 1 g/L peptone; 20 g/L glucose; 200 mg/L adenine) 
liquid media. Cultures were harvested at an A600 between 20 
0.5 and 1.5. Cells were collected by centrifugation at 
2,500xg for 5 minutes at 4 ° C., and resuspended in ice-cold, 
sterile dH20. Cells were pelleted again as above and resus-
pended in IM sorbitol. Forty µL of yeast suspension was 
mixed with 0.5 to 1 µg plasmid DNA (in <5 µL dH20) in a 25 
pre-chilled 0.5 mL tube, and transferred to a chilled cuvette 
with a 0.2 cm electrode gap. One pulse at 1.5 kV, 25 µF, and 
200 Ohms was applied by an Eppendorf Electroporator 
(model 2510). A mixture of 500 µL ofYPAD/lM sorbitol 
was immediately added to the electroporated cells. Cells 30 
were allowed to recover at 30° C. for 1 hour, then spread 
onto SGI plates (1 g/1 bactocasamino acids; 7 g/1 yeast 
nitrogen base; 20 g/1 glucose; 20 mg/I tryptophan; and 20 g/1 
agar). Transformed colonies appeared after 3 to 6 days of 
incubation at 30° C. Recombinant plasmids were confirmed 35 
by PCR assays performed directly on randomly selected 
yeast colonies. 
For expression studies, one colony was added to SGI 
media (1 g/1 bactocasamino acids; 7 g/1 yeast nitrogen base; 
20 g/1 glucose; and 20 mg/I tryptophan) and grown at 30° C. 40 
for approximately 24 hours. An aliquot of this culture was 
diluted 1 :50 into 250 mL ofYPGE (10 g/1 bactopeptone; 10 
g/1 yeast extract; 5 g/1 glucose; and 3% ethanol by volume) 
and the cells were grown until all glucose was consumed. 
The absence of glucose was determined by placing a 200 µL 45 
at aliquot of culture into a 1.5 mL tube, inserting a DIAS TIX 
urinalysis reagent strip (Bayer, Elkhart, IN) for 30 seconds, 
and observing colorimetric changes indicating glucose lev-
els. Induction was initiated by the addition of 5 grams of 
galactose (final concentration of 2%). The cultures were 50 
maintained at 30° C. for an additional 16 hours before 
collecting the cells by centrifugation at 7,000xg for 10 
minutes. The pelleted cells were washed with 100 mL of 
TES buffer (50 mM Tris-HCI, pH 7.5; 1 mM EDTA; 0.6 M 
sorbitol). The cells were centrifuged as above, resuspended 55 
in 100 mL of TES-M (TES supplemented with 10 mM 
2-mercaptoethanol), and allowed to incubate at room tem-
perature for 10 minutes. The yeast cells were centrifuged 
again at 7,000xg for 10 minutes, and the pellet was resus-
pended in 2.5 mL extraction buffer (1 % bovine serum 60 
albumin, fraction V; 2 mM 2-mercaptoethanol; 1 mM phe-
nylmethylsulfonyl fluoride, all dissolved in TES). Glass 
beads (0.5 mm in diameter, Biospec Products, Inc., Bartles-
ville, Okla.) were added until skimming the surface of the 
cell suspension. Cell walls were disrupted manually by hand 65 
shaking in a cold room for 10 min at 30 second intervals 
separated by 30 second intervals on ice. Cell extracts were 
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transferred to a 50 mL centrifuge tube, the glass beads were 
washed three times with 5 mL of extraction buffer, and the 
washes were pooled with the original cell extracts. 
Microsomes were prepared by differential centrifugation at 
10,000 g for 10 minutes at 4° C. to remove cellular debris, 
followed by centrifugation at 100,000xg for 70 minutes at 4 ° 
C., and microsomal pellets were resuspended in 1.5 mL 
TEG-M buffer (50 mM Tris-HCI, pH 7.5; 1 mM EDTA; 20% 
glycerol; and 1.5 mM 2-mercaptoethanol) and stored frozen 
at -80° C. until further assayed. 
CO Difference Spectra 
Fe2+.co vs. Fe2 + difference spectroscopy (Omura and 
Sato, J. Biol. Chem. 239:2370-2378, 1964) was performed 
using 0.4 mL of microsomes suspended in 1.6 mL of 50 mM 
Tris-HCI, pH 7.5; 1 mM EDTA; and 20% glycerol. A small 
amount of the reducing agent, sodium dithionite, was added, 
and the mixture was distributed between two cuvettes. A 
baseline was recorded between 400 and 500 nm on a Perkin 
Elmer Lambda 18 UV/visible spectrophotometer. CO was 
then bubbled into the sample cuvette for 1 minute, and the 
difference spectrum recorded again. The amount of func-
tional P450 was estimated based on an absorbance coeffi-
cient of 91 mM- 1 ·cm-1 . 
5-epi-aristolochene-1,3-hydroxylase Assays 
5-epi-aristolochene-1,3-hydroxylase assays were per-
formed in 0.5 mL polyethylene tubes in 100 µL volumes. 
5-epi-aristolochene or 1-deoxycapsidiol dissolved in hexane 
was added to the tube, and the organic solvent was removed 
by incubation of the open tube at 30° C. 5-epi-aristolochene 
and 1-deoxycapsidiol were resuspended in 2 µL dimethyl 
sulfoxide before adding the reaction mixture. Reactions 
were carried out in 100 mM Tris-HCI, pH 7.5, to which 
microsomal protein was added to a final concentration of 1 
mg/mL. Reactions were initiated by the addition of 2 mM 
NADPH. The final concentration of 5-epi-aristolochene and 
1-deoxycapsidiol in these assays varied from 20 to 50 µM. 
After incubations for variable lengths of time at 30° C., the 
reactions were extracted with two volumes of ethyl acetate. 
The organic extracts were concentrated and evaluated by GC 
and GC-MS along with standards of 5-epi-aristolochene 
(Whitehead et al., Phytochemistry 28:775-779, 1989; Rising 
et al., J. Am. Chem. Soc. 122:1861-1866, 2000), 1-deoxy-
capsidiol (Whitehead et al., Phytochemistry 29:479-182, 
1990), and capsidiol (Whitehead et al., Phytochemistry 
26:1367-1369, 1987; Milat et al., Phytochemistry 30:2171-
2173, 1991). GC analysis was routinely performed with an 
HP5890 GC equipped with a Hewlett-Packard HP-5 capil-
lary colunm (30 mx0.25 mm, 0.25 µm phase thickness) and 
FID as described previously (Rising et al., J. Am. Chem. 
Soc. 122:1861-1866, 2000). GC-MS analysis was performed 
at the University of Kentucky Mass Spectrometry Facility 
using a Varian 3400 gas chromatograph and a Finnigan 
INCOS 50 quadrupole mass selective detector. The GC was 
equipped with a J&W DB-5 ms capillary colunm (15 
mx0.25 mm, 0.25 µm phase thickness) and run with He as 
the carrier gas (10 psi.). Splitless injections were done at an 
injection port temperature of 280° C. The column tempera-
ture was maintained at 40° C. for 1 minute and then 
increased to 280° C. at 10° C. per minute. Following 
separation by the GC colunm, samples were introduced 
directly into the electron impact ionization source. Mass 
spectra were acquired at 70 eV, scanning from 40-440 Dain 
1 second. 
Production of Cytochrome P450s 
Using the standard molecular techniques described 
herein, the isolation of additional cytochrome P450 coding 
sequences is readily accomplished. For example, using all or 
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a portion of the amino acid sequence of any of the disclosed 
P450s, one may readily design P450-specific oligonucle-
otide probes, including P450 degenerate oligonucleotide 
probes (i.e., a mixture of all possible coding sequences for 
a given amino acid sequence). These oligonucleotides may 
be based upon the sequence of either DNA strand and any 
appropriate portion of the P450 nucleotide sequence. Gen-
eral methods for designing and preparing such probes are 
provided, for example, in Ausubel et al., 2000, Current 
Protocols in Molecular Biology, Wiley Interscience, New 10 
York, and Berger and Kimmel, Guide to Molecular Cloning 
Techniques, 1987, Academic Press, New York. These oli-
gonucleotides are useful for P450 gene isolation, either 
through their use as probes capable of hybridizing to a P450 
complementary sequence, or as primers for various ampli- 15 
fication techniques, for example, polymerase chain reaction 
(PCR) cloning strategies. 
Hybridization techniques and screening procedures are 
well known to those skilled in the art and are described, for 
example, in Ausubel et al. (supra); Berger and Kimmel 20 
(supra); Chen et al. (Arch. Biochem. Biophys. 324:255, 
1995); and Sambrook et al. (Molecular Cloning: A Labora-
tory Manual, Cold Spring Harbor Laboratory Press, New 
York). If desired, a combination of different oligonucleotide 
probes may be used for the screening of a recombinant DNA 25 
library. The oligonucleotides may be detectably-labeled 
using methods known in the art and used to probe filter 
replicas from a recombinant DNA library. Recombinant 
DNA libraries are prepared according to methods well 
known in the art, for example, as described in Ausubel et al. 30 
(supra), or they may be obtained from commercial sources. 
As discussed above, P450 oligonucleotides may also be 
used as primers in a polymerase chain reaction (PCR) 
amplification cloning strategy. PCR methods are well known 
in the art and are described, for example, in PCR Technol- 35 
ogy, Erlich, ed., Stockton Press, London, 1989; PCR Pro-
tocols: A Guide to Methods and Applications, Innis et al., 
eds., Academic Press, Inc., New York, 1990; andAusubel et 
al. (supra). Primers are optionally designed to allow cloning 
of the amplified product into a suitable vector, for example, 40 
by including appropriate restriction sites at the 5' and 3' ends 
of the amplified fragment (as described herein). If desired, a 
P450 gene may be isolated using the PCR "RACE" tech-
nique, or Rapid Amplification of cDNAEnds (see, e.g., Innis 
et al. (supra)). By this method, oligonucleotide primers 45 
based on a P450 sequence are oriented in the 3' and 5' 
directions and are used to generate overlapping PCR frag-
ments. These overlapping 3'- and 5'-end RACE products are 
combined to produce an intact full-length cDNA. This 
method is described in Innis et al. (supra) and Frohman et al. 50 
(Proc. Natl. Acad. Sci. U.S.A. 85:8998, 1988). 
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suitable expression vehicle or with a plasmid construct 
engineered for increasing the expression of a P450 polypep-
tide in vivo. 
Those skilled in the field of molecular biology will 
appreciate that any of a wide variety of expression systems 
may be used to provide the recombinant protein. The precise 
host cell used is not critical to the invention. The P450 
protein may be produced in a prokaryotic host, for example, 
E. coli TB 1, or in a eukaryotic host, for example, Saccha-
romyces cerevisiae, insect cells, mammalian cells (for 
example, COS 1 or NIH 3T3 cells), or any of a number of 
plant cells including, without limitation, algae, tree species, 
ornamental species, temperate fruit species, tropical fruit 
species, vegetable species, legume species, monocots, 
dicots, or in any plant of commercial or agricultural signifi-
cance. Particular examples of suitable plant hosts include, 
but are not limited to, Conifers, Petunia, Tomato, Potato, 
Tobacco, Grape, Arabidopsis, Lettuce, Sunflower, Oilseed 
rape, Flax, Cotton, Sugarbeet, Celery, Soybean, Alfalfa, 
Medicago, Lotus, Vigna, Cucumber, Carrot, Eggplant, Cau-
liflower, Horseradish, Morning Glory, Poplar, Walnut, 
Apple, Asparagus, Grape, Rice, Maize, Millet, Onion, Bar-
ley, Orchard grass, Oat, Rye, Tobacco and Wheat. 
Such cells are available from a wide range of sources 
including: the American Type Culture Collection (Rockland, 
Md.); or from any of a number of seed companies, for 
example, W. Atlee Burpee Seed Co. (Warminster, Pa.), Park 
Seed Co. (Greenwood, S.C.), Johnny Seed Co. (Albion, 
Me.), or Northrup King Seeds (Harstville, S.C.). Descrip-
tions and sources of useful host cells are also found in Vasil 
I. K., Cell Culture and Somatic Cell Genetics of Plants, Vol 
I, II, ITT; Laboratory Procedures and Their Applications, 
Academic Press, New York, 1984; Dixon, R. A., Plant Cell 
Culture-A Practical Approach, IRL Press, Oxford Univer-
sity, 1985; Green et al., Plant Tissue and Cell Culture, 
Academic Press, New York, 1987; and Gasser and Fraley, 
Science 244:1293, 1989. 
For prokaryotic expression, DNA encoding a P450 poly-
peptide is carried on a vector operably liuked to control 
signals capable of effecting expression in the prokaryotic 
host. If desired, the coding sequence may contain, at its 5' 
end, a sequence encoding any of the known signal sequences 
capable of effecting secretion of the expressed protein into 
the periplasmic space of the host cell, thereby facilitating 
recovery of the protein and subsequent purification. Pro-
karyotes most frequently used are various strains of E. coli; 
however, other microbial strains may also be used. Plasmid 
vectors are used which contain replication origins, selectable 
markers, and control sequences derived from a species 
compatible with the microbial host. Examples of such vec-
tors are found in Pouwels et al. (supra) or Ausubel et al. 
(supra). Commonly used prokaryotic control sequences 
( also referred to as "regulatory elements") are defined herein 
to include promoters for transcription initiation, optionally 
Additional methods for identifying sequences encoding 
P450s are provided in Maughan et al. (Arch. Biochem. 
Biophys. 341:104-111, 1997) and Clark et al. (Plant Mo!. 
Biol. 33:875-885, 1997). 
Useful P450 sequences may be isolated from any appro-
priate organism. Confirmation of a sequence's relatedness to 
a P450 polypeptide disclosed herein may be accomplished 
55 with an operator, along with ribosome binding site 
sequences. Promoters commonly used to direct protein 
expression include the beta-lactamase (penicillinase), the 
lactose (lac), the tryptophan (Trp) (Goedde! et al., Nucl. 
by a variety of conventional methods, for example, by 
comparing the sequence with a known P450 sequence found 60 
in a database. In addition, the activity of any P450 may be 
evaluated according to any of the techniques described 
herein. 
P450 Polypeptide Expression 
P450 polypeptides may be produced by transformation of 65 
a suitable host cell with all or part of a P450 DNA (for 
example, anyone of the P450 cDNAs described herein) in a 
Acids Res. 8:4057, 1980), and the tac promoter systems, as 
well as the lambda-derived P.sub.L promoter and N-gene 
ribosome binding site (Simatake et al., Nature 292: 128, 
1981). 
One particular bacterial expression system for P450 pro-
duction is the E. coli pET expression system (Novagen). 
According to this expression system, DNA encoding a P450 
is inserted into a pET vector in an orientation designed to 
allow expression. Since the P450 gene is under the control 
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of the T7 regulatory signals, P450 expression is dependent 
on inducing the expression of T7 RNA polymerase in the 
host cell. This is typically achieved using host strains which 
express T7 RNA polymerase in response to IPTG induction. 
Once produced, recombinant P450 is then isolated according 5 
to standard methods known in the art, for example, those 
described herein. 
Another bacterial expression system for P450 production 
20 
in Ausubel et al. (supra). In one example, cDNA encoding 
the P450 is cloned into an expression vector which includes 
the dihydrofolate reductase (DHFR) gene. Integration of the 
plasmid and, therefore, the P450-encoding gene into the host 
cell chromosome is selected for by inclusion of 0.01-300 µM 
methotrexate in the cell culture medium (as described in 
Ausubel et al., supra). This dominant selection can be 
accomplished in most cell types. Recombinant protein 
expression can be increased by DHFR-mediated amplifica-is the pGEX expression system (Pharmacia). This system 
employs a GST gene fusion system that is designed for 
high-level expression of a gene or gene fragment as a fusion 
protein with rapid purification and recovery of the functional 
gene product. The P450 of interest is fused to the carboxyl 
terminus of the glutathione S-transferase protein from Schis-
tosoma japonicum and is readily purified from bacterial 
lysates by affinity chromatography using Glutathione Sep-
harose 48. Fusion proteins can be recovered under mild 
conditions by elution with glutathione. Cleavage of the 
glutathione S-transferase domain from the fusion protein is 
facilitated by the presence of recognition sites for site-
specific proteases upstream of this domain. For example, 
proteins expressed in pGEX-2T plasmids may be cleaved 
with thrombin; those expressed in pGEX-3x may be cleaved 
with factor Xa. 
10 tion of the transfected gene. Methods for selecting cell lines 
bearing gene amplifications are described in Ausubel et al. 
(supra); such methods generally involve extended culture in 
medium containing gradually increasing levels of metho-
trexate. DHFR-containing expression vectors commonly 
15 used for this purpose include pCVSEII-DHrF and 
pAdD26SV(A) (described in Ausubel et al., supra). Any of 
the host cells described above or, preferably, a DHFR-
deficient CHO cell line (for example, CHO DHFR cells, 
ATCC Accession Number CRL 9096) are among the host 
20 cells preferred for DHFR selection of a stably-transfected 
cell line or DHFR-mediated gene amplification. 
A cytochrome P450 may also be produced in insect cells, 
such cells include, without limitation, Spodoptera fru-
giperda (S0-9, Sf-21, or Drosophila melanogaster Schnei-
Other prokaryotic systems useful for expressing eukary-
otic P450s are described by Cooper (Mutat. Res. 454:45-52, 
2000) and Dong et al. (Arch. Biochem. Biophys. 327:254-
259, 1996). In addition, strategies for enhancing the pro-
karyotic expression of a cytochrome P450 in combination 
with cytochrome reductase are described in Porter et al. 
(Drug. Metab. Rev. 31:159-174, 1999). 
25 der (SL-2) cells. For P450 production, insect cells are 
typically infected with a baculovirus, for example, 
Autographa californica Multiple Nuclear Polyhcdrosis 
Virus (AcMNPV) containing an expression cassette for such 
a protein, e.g., cytochrome P450, at a multiplicity of infec-
For eukaryotic expression, the method of transformation 
or transfection and the choice of vehicle for expression of 
the P450 will depend on the host system selected. Transfor-
mation and transfection methods of numerous organisms, 
30 tion of 1 to 10. The infected cells are generally cultured in 
a standard insect cell culture medium for 24 to 48 hours prior 
to recovering the protein using standard molecular biology 
techniques. If desired, a P450 polypeptide may also be 
produced in insect cells directly transfected with a DNA 
35 construct containing an expression cassette encoding the 
P450. for example, the baker's yeast Saccharomyces cerevisiae, 
are described, e.g., in Ausubel et al. (supra); Weissbach and 
Weissbach, Methods for Plant Molecular Biology, Academic 
Press, 1989; Gelvin et al., Plant Molecular Biology Manual, 
Kluwer Academic Publishers, 1990; Kindle, K., Proc. Natl. 40 
Acad. Sci. U.S.A. 87:1228 (1990); Potrykns, I., Annu Rev. 
Plant Physiol. Plant Mo!. Biology 42:205 (1991); and Bio-
Rad (Hercules, Calif.) Technical Bulletin #1687 (Biolistic 
Particle Delivery Systems). Expression vehicles may be 
chosen from those provided, e.g., in Cloning Vectors: A 45 
Laboratory Manual (P.H. Pouwels et al., 1985, Supp. 1987); 
Gasser and Fraley (supra); Clontech Molecular Biology 
Catalog (Catalog 1992/93 Tools for the Molecular Biologist, 
Palo Alto, Calif.); and the references cited above. One 
preferred cukaryotic expression system is the mouse 3T3 50 
fibroblast host cell transfected with a pMAMneo expression 
vector (Clontech). pMAMneo provides: an RSV-LTR 
enhancer liuked to a dexamethasone-inducible MMTV-LTR 
promoter, an SV 40 origin of replication which allows rep-
lication in mammalian systems, a selectable neomycin gene, 
and SV 40 splicing and polyadenylation sites. DNA encoding 
a P450 is inserted into the pMAMneo vector in an orienta-
tion designed to allow expression. The recombinant P450 is 
then isolated as described below. Other preferable host cells 
which may be used in conjunction with the pMAMneo 
expression vehicle include COS cells and CHO cells (ATCC 
Accession Nos. CRL 1650 and CCL 61, respectively). 
Furthermore, any of the cytochrome P450s described 
herein may be produced in yeast, for example, Pichia 
pastoris. In order to produce the P450, yeast cells are 
transformed with an expression cassette containing, for 
example, a promoter such as the AOXl or phosphoglycerate 
kinase gene promoter, the P450 gene to be expressed, and a 
terminator. Such an expression cassette may contain an 
origin of replication or it may be integrated into the yeast 
genomic DNA. The expression cassette is generally intro-
duced by lithium acetate transformation or by the use of 
spheroplasts. In order to select for successfully transformed 
cells, the yeast are plated, for example, on minimal media 
which only allows yeast carrying the introduced expression 
cassette to grow. 
In addition, expression of recombinant proteins in yeast 
using a Hansenula polymorphs expression system is 
described in U.S. Pat. Nos. 5,741,674 and 5,672,487. 
A P450 may also be produced by a stably-transfected 
55 plant cell line or by a transgenic plant. Such genetically-
engineered plants are useful for a variety of industrial and 
agricultural applications as discussed below. Importantly, 
this invention is applicable to gymnosperms and angio-
sperms, and will be readily applicable to any new or 
60 improved transformation or regeneration method. 
A number of vectors suitable for stable transfection of 
Alternatively, if desired, a P450 is produced by a stably-
transfected mammalian cell line. A number of vectors suit-
able for stable transfection of mammalian cells are available 65 
to the public, e.g., see Pouwels et al. (supra); methods for 
constructing such cell lines are also publicly available, e.g., 
plant cells or for the establishment of transgenic plants are 
available to the public; such vectors are described in Pou-
wels et al. (supra), Weissbach and Weissbach (supra), and 
Gelvin et al. (supra). Methods for constructing such cell 
lines are described in, e.g., Weissbach and Weissbach (su-
pra), and Gelvin et al. (supra). Typically, plant expression 
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vectors include (1) a cloned P450 gene under the transcrip-
tional control of 5' and 3' regulatory sequences and (2) a 
dominant selectable marker. Such plant expression vectors 
may also contain, if desired, a promoter regulatory region 
(for example, one conferring inducible or constitutive 
expression, or environmentally- or developmentally-regu-
lated, or pathogen- or wound-inducible, or cell- or tissue-
specific expression), a transcription initiation start site, a 
ribosome binding site, an RNA processing signal, a tran-
scription termination site, and/or a polyadenylation signal. 
The P450 DNA sequence of the invention may, if desired, 
be combined with other DNA sequences in a variety of 
ways. The P450 DNA sequence of the invention may be 
employed with all or part of the gene sequences normally 
associated with a P450. In its component parts, a DNA 
sequence encoding a P450 is combined in a DNA construct 
having a transcription initiation control region capable of 
promoting transcription and translation in a host cell. 
In general, the constructs will involve regulatory regions 
functional in plants which provide for production of a P450 
as discussed herein. The open reading frame coding for the 
P450, or a functional fragment thereof, will be joined at its 
5' end to a transcription initiation regulatory region such as 
the sequence naturally found in the 5' upstream region of a 
P450 structural gene, for example, a CYP71D20 (SEQ ID 
N0:2) or CYP71D21 (SEQ ID N0:4) gene. Numerous other 
transcription initiation regions are available which provide 
for constitutive or inducible regulation. 
For applications when developmental, cell, tissue, hor-
monal, environmental, or pathogen-inducible expression are 
desired, appropriate 5' upstream non-coding regions are 
obtained from other genes; for example, from genes regu-
lated during seed development, embryo development, leaf 
development, or in response to a pathogen. 
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regulatory sequences, which have been shown to be regu-
lated in response to the environment, hormones, and/or 
developmental cues. These include gene promoters that are 
responsible for heat-regulated gene expression (see, e.g., 
Callis et al., Plant Physiol. 88:965, 1988; Takahashi and 
Komeda, Mo!. Gen. Genet. 219:365, 1989; and Takahashi et 
al., Plant J. 2:751, 1992); light-regulated gene expression 
( e.g., the pea rbcS-3A described by Kuhlemeier et al. (Plant 
Cell 1:471, 1989); the maize rbcS promoter described by 
10 Schaffner and Sheen (Plant Cell 3:997, 1991); or the chlo-
rophyll alb-binding protein gene found in pea described by 
Simpson et al. (EMBO J. 4:2723, 1985)); hormone-regu-
lated gene expression (for example, the abscisic acid (ABA) 
15 responsive sequences from the Em gene of wheat described 
by Marcotte et al. (Plant Cell 1:969, 1989); the ABA-
inducible HVAl and HVA22, and the rd29A promoters 
described for barley and Arabidopsis by Straub et al. (Plant 
Cell 6:617, 1994), Shen et al. (Plant Cell 7:295, 1994)); and 
20 wound-induced gene expression (for example, of wunI 
described by Siebertz et al. (Plant Cell 1:961, 1989); or 
organ-specific gene expression (for example, of the tuber-
specific storage protein gene described by Roshal et al. 
(EMBO J. 6: 1155, 1987); the 23-kDa zein gene from maize 
25 described by Schemthaner et al. (EMBO J. 7: 1249, 1988); or 
the French bean beta-phaseolin gene described by Bustos et 
al. (Plant Cell 1:839, 1989); and pathogen-inducible gene 
expression described by Chappell et al. in U.S. Ser. Nos. 
08/471,983; 08/443,639; and 08/577,483; hereby incorpo-
30 rated by reference. 
Plant expression vectors may also optionally include 
RNA processing signals, for example, intrans, which have 
been shown to be important for efficient RNA synthesis and 
accumulation (Callis et al., Genes and Dev. 1:1183, 1987). 
35 The location of the RNA splice sequences can dramatically 
influence the level oftransgene expression in plants. In view 
of this fact, an intron may be positioned upstream or 
downstream of a P450-encoding sequence in the transgene 
Regulatory transcript termination regions may also be 
provided in DNA constructs of this invention as well. 
Transcript termination regions may be provided by the DNA 
sequence encoding a P450 or any convenient transcription 
termination region derived from a different gene source. The 
transcript termination region will contain preferably at least 40 
1-3 kb of sequence 3' to the structural gene from which the 
termination region is derived. 
to modulate levels of gene expression. 
In addition to the aforementioned 5' regulatory control 
sequences, the expression vectors may also include regula-
tory control regions which are generally present in the 3' 
regions of plant genes (Thornburg et al., Proc. Natl. Acad. 
Sci. U.S.A. 84:744, 1987; An et al., Plant Cell 1:115, 1989). 
An example of a useful plant promoter according to the 
invention is a caulimovirus promoter, such as, a cauliflower 
mosaic virus (CaMV) promoter. These promoters confer 
high levels of expression in most plant tissues, and the 
activity of these promoters is not dependent on virally 
encoded proteins. CaMV is a source for both the 35S and 
19S promoters. In most tissues of transgenic plants, the 
CaMV 35S promoter is a strong promoter (see, e.g., Odell et 
al., Nature 313:810, 1985). The CaMV promoter is also 
highly active in monocots (see, e.g., Dekeyser et al., Plant 
Cell 2:591, 1990; Terada and Shimamoto, Mo!. Gen. Genet. 
220:389, 1990). Moreover, activity of this promoter can be 
further increased (i.e., between 2-10 fold) by duplication of 
the CaMV 35S promoter (see e.g., Kay et al., Science 
236:1299, 1987; Ow et al., Proc. Natl. Acad. Sci. U.S.A. 
84:4870, 1987; and Fang et al., Plant Cell 1:141, 1989). 
Other useful plant promoters include, without limitation, the 
nopaline synthase promoter (An et al., Plant Physiol. 88: 54 7, 
1988) and the octopine synthase promoter (Fromm et al., 
Plant Cell 1:977, 1989). 
For certain applications, it may be desirable to produce 
the P450 gene product in an appropriate tissue, at an 
appropriate level, or at an appropriate developmental time. 
For this purpose, there is an assortment of gene promoters, 
each with its own distinct characteristics embodied in its 
45 For example, the 3' terminator region may be included in the 
expression vector to increase stability of the mRNA. One 
such terminator region may be derived from the Pl-11 
terminator region of potato. In addition, other commonly 
used terminators are derived from the octopine or nopaline 
50 synthase signals. 
The plant expression vector also typically contains a 
dominant selectable marker gene used to identify those cells 
that have become transformed. Useful selectable genes for 
plant systems include genes encoding antibiotic resistance 
55 genes, for example, those encoding resistance to hygromy-
cin, kanamycin, bleomycin, G418, streptomycin, or spec-
tinomycin. Genes required for photosynthesis may also be 
used as selectable markers in photosynthetic-deficient 
strains. Alternatively, the green-fluorescent protein from the 
60 jellyfish Aequorea victoria may be used as a selectable 
marker (Sheen et al., Plant J. 8:777, 1995; Chiu et al., 
Current Biology 6:325, 1996). Finally, genes encoding her-
bicide resistance may be used as selectable markers; useful 
herbicide resistance genes include the bar gene encoding the 
65 enzyme phosphinothricin acetyltransferase and conferring 
resistance to the broad-spectrum herbicide BASTA (Hoechst 
AG, Frankfurt, Germany). 
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Efficient use of selectable markers is facilitated by a 
determination of the susceptibility of a plant cell to a 
particular selectable agent and a determination of the con-
centration of this agent which effectively kills most, if not 
all, of the transformed cells. Some useful concentrations of 
antibiotics for tobacco transformation include, e.g., 75-100 
µg/mL (kanamycin), 20-50 µg/mL (hygromycin), or 5-10 
ng/mL (bleomycin). A useful strategy for selection oftrans-
formants for herbicide resistance is described, e.g., by Vasil 
et al., supra. 
It should be readily apparent to one skilled in the art of 
molecular biology, especially in the field of plant molecular 
biology, that the level of gene expression is dependent, not 
only on the combination of promoters, RNA processing 
signals, and terminator elements, but also on how these 
elements are used to increase the levels of selectable marker 
gene expression. 
Plant Transformation 
24 
In another example, plant cells may be transformed by 
shooting into the cell tungsten microprojectiles on which 
cloned DNA is precipitated. In the Biolistic Apparatus 
(Bio-Rad) used for the shooting, a gunpowder charge (22 
caliber Power Piston Tool Charge) or an air-driven blast 
drives a plastic macroprojectile through a gun barrel. An 
aliquot of a suspension of tungsten particles on which DNA 
has been precipitated is placed on the front of the plastic 
macroprojectile. The latter is fired at an acrylic stopping 
10 plate that has a hole through it that is too small for the 
macroprojectile to pass through. As a result, the plastic 
macroprojectile smashes against the stopping plate, and the 
tungsten microprojectiles continue toward their target 
through the hole in the plate. For the present invention, the 
15 target can be any plant cell, tissue, seed, or embryo. The 
DNA introduced into the cell on the microprojectiles 
becomes integrated into either the nucleus or the chloroplast. 
Upon construction of the plant expression vector, several 
standard methods are available for introduction of the vector 20 
In general, transfer and expression of trans genes in plant 
cells are now routine practices to those skilled in the art, and 
have become major tools to carry out gene expression 
studies in plants and to produce improved plant varieties of into a plant host, thereby generating a transgenic plant. 
These methods include (1) Agrobacterium-mediated trans-
formation (A. tumefaciens or A. rhizogenes) (see, e.g., Lich-
tenstein and Fuller, In: Genetic Engineering, vol. 6, P W J 
Rigby, ed, London, Academic Press, 1987; and Lichtenstein, 
C. P., and Draper, J., In: DNA Cloning, Vol II, D. M. Glover, 
ed, Oxford, IRI Press, 1985); (2) the particle delivery system 
(see, e.g., Gordon-Kamm et al., Plant Cell 2:603, 1990; or 
BioRad Technical Bulletin 1687, supra); (3) microinjection 
protocols (see, e.g., Green et al., supra); ( 4) polyethylene 
glycol (PEG) procedures (see, e.g., Draper et al., Plant Cell 
Physiol. 23:451, 1982; or e.g., Zhang and Wu, Theor. Appl. 
Genet. 76:835, 1988); (5) liposome-mediated DNA uptake 
(see, e.g., Freeman et al., Plant Cell Physiol. 25: 1353, 1984); 
(6) electroporation protocols (see, e.g., Gelvin et al., supra; 
Dekeyser et al., supra; Fromm et al., Nature 319:791, 1986; 
Sheen, Plant Cell 2:1027, 1990; or Jang and Sheen, Plant 
Cell 6: 1665, 1994); and (7) the vortexing method (see, e.g., 
Kindle, supra). The method of transformation is not critical 
to the present invention. Any method which provides for 
efficient transformation may be employed. As newer meth-
ods are available to transform crops or other host cells, they 
may be directly applied. 
The following is an example outlining one particular 
technique, an Agrobacterium-mediated plant transforma-
tion. By this technique, the general process for manipulating 
genes to be transferred into the genome of plant cells is 
carried out in two phases. First, cloning and DNA modifi-
cation steps arc carried out in E. coli, and the plasmid 
containing the gene construct of interest is transferred by 
conjugation or electroporation into Agrobacterium. Second, 
the resulting Agro bacterium strain is used to transform plant 
cells. Thus, for the generalized plant expression vector, the 
plasmid contains an origin of replication that allows it to 
replicate in Agro bacterium and a high copy number origin of 
replication functional in E. coli. This permits facile produc-
tion and testing of transgenes in E. coli prior to transfer to 
Agrobacterium for subsequent introduction into plants. 
Resistance genes can be carried on the vector, one for 
selection in bacteria, for example, streptomycin, and another 
that will function in plants, for example, a gene encoding 
kanamycin resistance or herbicide resistance. Also present 
on the vector are restriction endonuclease sites for the 
addition of one or more transgenes and directional T-DNA 
border sequences which, when recognized by the transfer 
functions of Agrobacterium, delimit the DNA region that 
will be transferred to the plant. 
agricultural or commercial interest. 
Transgenic Plant Regeneration 
Plants cells transformed with plant expression vectors can 
25 be regenerated, for example, from single cells, callus tissue, 
or leaf discs according to standard plant tissue culture 
techniques. It is well known in the art that various cells, 
tissues, and organs from almost any plant can be success-
fully cultured to regenerate an entire plant; such techniques 
30 are described, e.g., in Vasil (supra), Green et al. (supra), 
Weissbach and Weissbach (supra) and Gelvin et al. (supra). 
In one particular example, a cloned P450, under the 
control of the EAS4 promoter and the nopaline synthase 
terminator and carrying a selectable marker (for example, 
35 kanamycin resistance), is transformed into Agrobacterium. 
Transformation of leaf discs (for example, of tobacco leaf 
discs), with vector-containing Agro bacterium is carried out 
as described by Horsch et al. (Science 227:1229, 1985). 
Putative transformants are selected after a few weeks (for 
40 example, 3 to 5 weeks) on plant tissue culture media 
containing kanamycin (e.g., 100 µg/mL). Kanamycin-resis-
tant shoots are then placed on plant tissue culture media 
without hormones for root initiation. Kanamycin-resistant 
plants are then selected for greenhouse growth. If desired, 
45 seeds from self-fertilized transgenic plants can then be 
sowed in soil-less medium and grown in a greenhouse. 
Kanamycin-resistant progeny are selected by sowing surface 
sterilized seeds on hormone-free kanamycin-containing 
media. Analysis for the integration of the transgene is 
50 accomplished by standard techniques (see, for example, 
Ausubel et al. (supra); Gelvin et al. (supra)). 
Transgenic plants expressing the selectable marker are 
then screened for transmission of the transgene DNA by 
standard immunoblot and DNA detection techniques. Each 
55 positive transgenic plant and its transgenic progeny is 
unique in comparison to other transgenic plants established 
with the same trans gene. Integration of the transgene DNA 
into the plant genomic DNA is in most cases random, and the 
site of integration can profoundly affect the levels and the 
60 tissue and developmental patterns of transgene expression. 
Consequently, a number of transgenic lines are usually 
screened for each transgene to identify and select plants with 
the most appropriate expression profiles. 
Transgenic lines are generally evaluated for levels of 
65 transgene expression. Expression at the RNA level is deter-
mined initially to identify and quantitate expression-positive 
plants. Standard techniques for RNA analysis are employed 
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and include PCR amplification assays using oligonucleotide 
primers designed to amplify only transgene RNA templates 
and solution hybridization assays using transgene-specific 
probes (see, e.g., Ausubel et al. (supra)). The RNA-positive 
plants are then analyzed for protein expression by Western 
immunoblot analysis using specific antibodies to the P450 
(see, e.g., Ausubel et al., supra). In addition, in situ hybrid-
ization and immunocytochemistry according to standard 
protocols can be done using transgene-specific nucleotide 
probes and antibodies, respectively, to localize sites of 10 
expression within transgenic tissue. 
Once the recombinant P450 is expressed in any cell or in 
a transgenic plant (for example, as described above), it may 
be isolated, e.g., using affinity chromatography. In one 15 
example, an anti-P450 antibody ( e.g., produced as described 
in Ausubel et al., supra, or by any standard technique) may 
be attached to a column and used to isolate the polypeptide. 
Lysis and fractionation of P450-producing cells prior to 
affinity chromatography may be performed by standard 20 
methods (see, e.g., Ausubel et al., supra). Once isolated, the 
recombinant protein can, if desired, be further purified, for 
example, by high performance liquid chromatography (see, 
e.g., Fisher, Laboratory Techniques in Biochemistry and 
Molecular Biology, eds., Work and Burdon, Elsevier, 1980). 25 
These general techniques of polypeptide expression and 
purification can also be used to produce and isolate useful 
P450 fragments or analogs. 
Use 
The aforementioned cytochrome P450 polypeptides of the 30 
invention are useful in the biosynthesis of hormones, lipids, 
and secondary metabolites, and may also help plants tolerate 
potentially harmful exogenous chemicals such as herbicides, 
pesticides, and pollutants. In addition, such cytochrome 35 
P450 polypeptides are useful in the chemical defense of 
plants against insects, as well as against bacterial, viral, and 
fungal infection. 
Engineering Plant Disease Resistance 
Plasmid constructs designed for the expression of a P450 40 
gene product are useful, for example, for activating plant 
defense pathways that confer anti-pathogenic properties to a 
transgenic plant, for example, the production of phytoalex-
ins. P450 genes that are isolated from a host plant (e.g., 
Nicotiana) may be engineered for expression in the same 45 
plant, a closely related species, or a distantly related plant 
species. For example, a P450 gene may be engineered for 
constitutive low-level expression and then transformed into 
a Nicotiana host plant. Alternatively, the P450 gene may be 
engineered for expression in other solanaceous plants, 50 
including, but not limited to, potato and tomato. To achieve 
pathogen resistance, it is important to express a P450 protein 
at an effective level. Evaluation of the level of pathogen 
protection conferred to a plant by ectopic expression of the 
P450 gene is determined according to conventional methods 
and assays. 
<160> NUMBER OF SEQ ID NOS, 43 
<210> SEQ ID NO 1 
<211> LENGTH, 473 
<212> TYPE, PRT 
SEQUENCE LISTING 
<213> ORGANISM: Nicotiana tabacum 
26 
INDUSTRIAL APPLICATIONS 
The invention also includes engineering host cells to 
include novel isoprenoid metabolic pathways useful in the 
production of new isoprenoid compounds. By introducing 
genes encoding an isoprenoid synthase (as disclosed in U.S. 
Pat. No. 5,824,774 and WO 00/17327) and a cytochrome 
P450, an acetyltransferase, a methyl transferase, a fatty 
acyltransferase, or a combination thereof, various isoprenoid 
reaction products may be modified, controlled, or manipu-
lated, resulting in enhancement of production of numerous 
isoprenoid reaction products, for example, the production of 
novel monoterpenes, diterpenes, and sesquiterpenes. Such 
compounds are useful as phytoalexins, insecticides, per-
fumes, and pharmaceuticals such as anti-bacterial and fungal 
agents. 
In one working example, an isoprenoid synthase or a 
chimeric isoprenoid synthase (as disclosed in U.S. Pat. No. 
5,824,774 and WO 00/17327) and a P450 gene are intro-
duced into yeast, for example, using any of the procedures 
described herein. If desired, such cells may also express, 
either independently or in combination, an acetyltransferase 
(see, for example, Walker et al., Proc. Natl. Acad. Sci. 
U.S.A. 18:583-587, 2000), a methylase transferase gene 
(see, for example, Diener et al., Plant Cell 12:853-870, 
2000), or a fatty acyltransferase gene, as well as a 
cytochrome reductase. Cells are then cultured under stan-
dard conditions and the production of isoprenoid com-
pounds is assayed according to methods known in the art. 
Isoprenoid compounds are further purified according to 
methods well known in the art. Cells expressing novel 
isoprenoid compounds are taken as useful in the invention. 
Such methods provide a unique approach for producing 
novel isoprenoid starting materials and end products. Either 
prokaryotic or cukaryotic cells transformed with any of the 
aforementioned enzymes ( or combinations thereof) may be 
used. Moreover, isoprenoid compounds may be produced in 
any number of ways known in the art including an in vitro 
combination of purified enzymes with an appropriate sub-
strate or direct fermentation using a host cell which 
expresses any combination of the aforementioned enzymes 
and the appropriate substrates sufficient to drive production 
of isoprenoid compounds. 
The invention is also useful for the production of insect 
attractants and deterrents, which may either deter insect 
pests or attract insect predators. In addition, the invention is 
also useful for generating novel flavorings and perfumes. 
Other Embodiments 
From the foregoing description, one skilled in the art can 
easily ascertain the essential characteristics of this invention, 
and can make various changes and modifications of the 
invention to adapt it to various usages and conditions. Thus, 
other embodiments are also within the claims. 
All publications and patents mentioned in this specifica-
tion are herein incorporated by reference to the same extent 
as if each individual publication or patent was specifically 
and individually indicated to be incorporated by reference. 
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-continued 
<400> SEQUENCE, 1 
Met Gln Phe Phe Ser Leu Val Ser Ile Phe Leu Phe Leu Ala Phe Leu 
1 5 10 15 
Phe Leu Leu Arg Lys Trp Lys Asn Ser Asn Ser Gln Ser Lys Lys Leu 
20 25 30 
Pro Pro Gly Pro Trp Lys Ile Pro Ile Leu Gly Ser Met Leu His Met 
35 40 45 
Ile Gly Gly Glu Pro His His Val Leu Arg Asp Leu Ala Lys Lys Tyr 
50 55 60 
Gly Pro Leu Met His Leu Gln Leu Gly Glu Ile Ser Ala Val Val Val 
65 70 75 80 
Thr Ser Arg Asp Met Ala Lys Glu Val Leu Lys Thr His Asp Val Val 
85 90 95 
Phe Ala Ser Arg Pro Lys Ile Val Ala Met Asp Ile Ile Cys Tyr Asn 
100 105 110 
Gln Ser Asp Ile Ala Phe Ser Pro Tyr Gly Asp His Trp Arg Gln Met 
115 120 125 
Arg Lys Ile Cys Val Met Glu Leu Leu Asn Ala Lys Asn Val Arg Ser 
130 135 140 
Phe Ser Ser Ile Arg Arg Asp Glu Val Val Arg Leu Ile Asp Ser Ile 
145 150 155 160 
Arg Ser Asp Ser Ser Ser Gly Glu Leu Val Asn Phe Thr Gln Arg Ile 
165 170 175 
Ile Trp Phe Ala Ser Ser Met Thr Cys Arg Ser Ala Phe Gly Gln Val 
180 185 190 
Leu Lys Gly Gln Asp Ile Phe Ala Lys Lys Ile Arg Glu Val Ile Gly 
195 200 205 
Leu Ala Glu Gly Phe Asp Val Val Asp Ile Phe Pro Thr Tyr Lys Phe 
210 215 220 
Leu His Val Leu Ser Gly Met Lys Arg Lys Leu Leu Asn Ala His Leu 
225 230 235 240 
Lys Val Asp Ala Ile Val Glu Asp Val Ile Asn Glu His Lys Lys Asn 
245 250 255 
Leu Ala Ala Gly Lys Ser Asn Gly Ala Leu Glu Asp Met Phe Ala Ala 
260 265 270 
Gly Thr Glu Thr Ser Ser Thr Thr Thr Val Trp Ala Met Ala Glu Met 
275 280 285 
Met Lys Asn Pro Ser Val Phe Thr Lys Ala Gln Ala Glu Val Arg Glu 
290 295 300 
Ala Phe Arg Asp Lys Val Ser Phe Asp Glu Asn Asp Val Glu Glu Leu 
305 310 315 320 
Lys Tyr Leu Lys Leu Val Ile Lys Glu Thr Leu Arg Leu His Pro Pro 
325 330 335 
Ser Pro Leu Leu Val Pro Arg Glu Cys Arg Glu Asp Thr Asp Ile Asn 
340 345 350 
Gly Tyr Thr Ile Pro Ala Lys Thr Lys Val Met Val Asn Val Trp Ala 
355 360 365 
Leu Gly Arg Asp Pro Lys Tyr Trp Asp Asp Ala Glu Ser Phe Lys Pro 
370 375 380 
Glu Arg Phe Glu Gln Cys Ser Val Asp Phe Phe Gly Asn Asn Phe Glu 
385 390 395 400 
Phe Leu Pro Phe Gly Gly Gly Arg Arg Ile Cys Pro Gly Met Ser Phe 
405 410 415 
28 
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-continued 
Gly Leu Ala Asn Leu Tyr Leu Pro Leu Ala Gln Leu Leu Tyr His Phe 
420 425 430 
Asp Trp Lys Leu Pro Thr Gly Ile Met Pro Arg Asp Leu Asp Leu Thr 
435 440 445 
Glu Leu Ser Gly Ile Thr Ile Ala Arg Lys Gly Asp Leu Tyr Leu Asn 
450 455 460 
Ala Thr Pro Tyr Gln Pro Ser Arg Glu 
465 470 
<210> SEQ ID NO 2 
<211> LENGTH, 1660 
<212> TYPE, DNA 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 2 
ggatggtcta ataatcctcc atttatctcc gaaaatgcaa ttcttcagct tggtttccat 
tttcctcttc ctagctttcc tatttttgtt gaggaaatgg aagaactcca atagccaaag 
caaaaaattg ccaccaggtc catggaaaat accaatacta ggaagtatgc ttcatatgat 
tggtggagaa ccgcaccatg tccttagaga tttagccaaa aaatatggac cacttatgca 
ccttcagtta ggtgaaattt ctgcagttgt ggttacttct agggacatgg caaaagaagt 
gctaaaaact catgacgtcg tttttgcatc taggcctaaa attgtagcca tggacattat 
ctgttataac cagtccgaca ttgcctttag cccttatggc gaccactgga gacaaatgcg 
taaaatttgt gtcatggaac ttctcaatgc aaagaatgtt cggtctttca gctccatcag 
acgtgatgaa gtcgttcgtc tcattgactc tatccggtca gattcttctt caggtgagct 
agttaatttt acgcagagga tcatttggtt tgcaagctcc atgacgtgta gatcagcatt 
tgggcaagta ctcaaggggc aagacatatt tgccaaaaag atcagagaag taataggatt 
agcagaaggc tttgatgtgg tagacatctt ccctacatac aagtttcttc atgttctcag 
tgggatgaag cgtaaacttt tgaatgccca ccttaaggta gacgccattg ttgaggatgt 
catcaacgag cacaagaaaa atcttgcagc tggcaaaagt aatggcgcat tagaggacat 
gtttgctgcc ggaacagaaa cttcatcaac aacaactgta tgggctatgg ctgaaatgat 
gaagaatcca agtgtattca ccaaagctca agcagaagtg cgagaagcct ttagggacaa 
agtatctttt gatgaaaatg atgtggagga gctgaaatac ttaaagttag tcattaaaga 
aactttgaga cttcatccac cgtctccact tttggtccca agagaatgca gggaagatac 
ggatataaac ggctacacta ttcctgcaaa gaccaaagtt atggttaatg tttgggcatt 
gggaagagat ccaaaatatt gggatgacgc ggaaagcttt aagccagaga gatttgagca 
atgctctgtg gatttttttg gtaataattt tgagtttctt ccctttggcg gtggacggag 
aatttgtcct ggaatgtcat ttggtttagc taatctttac ttgccattgg ctcaattact 
ctatcacttt gactggaaac tcccaaccgg aatcatgcca agagacttag acttgaccga 
attatcggga ataactattg ctagaaaggg tgacctttac ttaaatgcca ctccttatca 
accttctcga gagtaattca atattggcat aaacatttta aatttccttc atcaacctca 
atattgtaca ataatcattc ttctggtgtt ataggcttta tcgatttcca atacatgtat 
tctttattaa aaaatgtatc acattccatg tagaaggagg acgcaccaat taattgtgcc 
atgattttag ggtaacttgt tccatcttaa aaaaaaaaaa 
30 
60 
120 
180 
240 
300 
360 
420 
480 
540 
600 
660 
720 
780 
840 
900 
960 
1020 
1080 
1140 
1200 
1260 
1320 
1380 
1440 
1500 
1560 
1620 
1660 
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<210> SEQ ID NO 3 
<211> LENGTH, 474 
<212> TYPE, PRT 
31 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 3 
-continued 
Met Glu Phe Phe Ser Leu Val Ser Ile Phe Leu Phe Leu Ser Phe Leu 
1 5 10 15 
Phe Leu Leu Arg Lys Cys Lys Asn Ser Asn Ser Gln Thr Lys Gln Leu 
20 25 30 
Pro Pro Gly Pro Trp Lys Ile Pro Ile Leu Gly Ser Met Leu His Met 
35 40 45 
Leu Gly Gly Glu Pro His His Ile Leu Arg Asp Leu Ala Lys Lys Tyr 
50 55 60 
Gly Pro Ile Met His Leu Gln Phe Gly Glu Ile Ser Ala Val Val Val 
65 70 75 80 
Thr Ser Arg Glu Met Ala Lys Glu Val Leu Lys Thr His Asp Val Val 
85 90 95 
Phe Ala Ser Arg Pro Lys Ile Val Ala Met Asp Ile Ile Cys Tyr Asn 
100 105 110 
Gln Ser Asp Ile Ala Phe Ser Pro Tyr Gly Asp His Trp Arg Gln Met 
115 120 125 
Arg Lys Ile Cys Val Met Glu Leu Leu Asn Ala Lys Asn Val Arg Ser 
130 135 140 
Phe Ser Ser Ile Arg Arg Asp Glu Val Val Arg Leu Ile Asp Ser Ile 
145 150 155 160 
Arg Ser Asp Ser Ser Ser Gly Glu Leu Val Asn Phe Thr Gln Arg Ile 
165 170 175 
Ile Trp Phe Ala Ser Ser Met Thr Cys Arg Ser Ala Phe Gly Gln Val 
180 185 190 
Leu Lys Gly Gln Asp Val Phe Ala Lys Lys Ile Arg Glu Val Ile Gly 
195 200 205 
Leu Ala Glu Gly Phe Asp Val Ala Asp Ile Phe Pro Ser Tyr Lys Phe 
210 215 220 
Leu His Val Leu Ser Gly Met Lys Arg Lys Leu Leu Asn Ala His Leu 
225 230 235 240 
Lys Val Asp Ala Ile Val Glu Asp Val Ile Asn Glu His Lys Lys Asn 
245 250 255 
Leu Ala Thr Gly Lys Thr Asn Gly Ala Leu Gly Glu Asp Met Phe Ala 
260 265 270 
Ala Gly Thr Glu Thr Ser Ser Thr Thr Thr Val Trp Ala Met Ala Glu 
275 280 285 
Met Met Lys Asn Pro Asn Val Phe Asn Lys Ala Gln Ala Glu Val Arg 
290 295 300 
Glu Thr Phe Lys Asp Lys Val Thr Phe Asp Glu Ile Asp Ala Glu Glu 
305 310 315 320 
Leu Glu Tyr Leu Lys Leu Val Ile Lys Glu Thr Leu Arg Leu His Pro 
325 330 335 
Pro Ser Pro Leu Leu Val Pro Arg Glu Cys Arg Glu Asp Thr Asp Ile 
340 345 350 
Asn Gly Tyr Thr Ile Pro Ala Lys Thr Lys Val Met Val Asn Val Trp 
355 360 365 
Ala Leu Gly Arg Asp Pro Lys Tyr Trp Asp Asp Ala Glu Ser Phe Lys 
370 375 380 
32 
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-continued 
Pro Glu Arg Phe Glu Gln Cys Ser Val Asp Phe Phe Gly Asn Asn Phe 
385 390 395 400 
Glu Phe Leu Pro Phe Gly Gly Gly Arg Arg Ile Cys Pro Gly Met Ser 
405 410 415 
Phe Gly Leu Ala Asn Leu Tyr Leu Pro Leu Ala Gln Leu Leu Tyr His 
420 425 430 
Phe Asp Trp Lys Leu Pro Ser Gly Met Met Pro Gly Asp Leu Asp Leu 
435 440 445 
Thr Glu Leu Ala Gly Ile Thr Ile Ala Arg Lys Gly Asp Leu Tyr Leu 
450 455 460 
Met Ala Thr Pro Tyr Gln Pro Ser Arg Glu 
465 470 
<210> SEQ ID NO 4 
<211> LENGTH, 1614 
<212> TYPE, DNA 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 4 
ggatggtcta ataatcctcc atttatctcc caaaatggaa ttcttcagct tggtttccat 
attcctattc ctatctttcc tctttttgtt aaggaaatgt aagaactcca atagccaaac 
caaacaattg cctccaggtc catggaaaat accaatacta ggaagtatgc ttcatatgct 
tggtggagaa ccacaccata tccttaggga tttagccaaa aaatatggac caattatgca 
ccttcagttt ggtgaaattt ctgcagttgt ggttacttct agggagatgg caaaagaagt 
gctaaaaact catgacgtag tttttgcatc taggcctaaa attgtggcca tggacattat 
ctgttataac cagtctgata tcgcctttag cccttatggc gatcactgga gacaaatgcg 
taaaatttgt gtcatggaac ttcttaatgc aaagaatgtt cggtctttca gctcgatcag 
acgtgatgaa gtcgttcgtc tcattgactc tattcgatca gattcttctt ctggtgagct 
agttaatttt acgcaaagga tcatttggtt cgcgagctcc atgacgtgta gatcagcatt 
tgggcaagta cttaaggggc aagacgtatt tgccaaaaag attagagaag taatagggtt 
agcagaaggc tttgatgtgg ccgatatctt cccttcatac aagtttcttc atgttctcag 
tggaatgaag cgtaaacttc tgaatgccca ccttaaggta gatgccattg ttgaggatgt 
catcaacgag cacaagaaaa atcttgcaac tgggaaaact aatggagcat taggagacat 
gtttgctgcc ggaacagaaa cttcatcaac aacaactgta tgggctatgg ctgaaatgat 
gaagaatcca aatgtattca acaaagctca ggcagaagtg agagaaacct ttaaagacaa 
agtaacattt gatgaaattg atgcagagga gctggaatac ttaaagttag ttattaaaga 
aactttgaga cttcatccac cgtctccact tttggtccca agagaatgta gggaagatac 
agatattaac ggctacacta ttcctgcgaa gaccaaagtt atggttaatg tttgggcatt 
gggaagagat ccaaaatatt gggatgacgc agaaagcttt aagccagaga gatttgagca 
atgctctgtg gatttttttg gtaataattt tgagtttctt ccctttggcg gtggacggag 
aatatgtcct ggtatgtcat ttggtttagc taatctttac ttgccattgg ctcaattgct 
atatcacttt gattggaaac tcccgagcgg aatgatgccc ggagacttgg acttgactga 
attagctgga ataacaattg ctagaaaggg tgacctttac ttaatggcta ctccttatca 
accttctcgc gaataattta atggcatcag gttttttaat tccattgtca acctcactat 
tgtacaagct ttctgatgtt tcaggttttg ccgatttgta ataaatgtag tttttataat 
atgtatcata cccatgtaga agagggacga ttaattagtt gtaaaaaaaa aaaa 
34 
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<210> SEQ ID NO 5 
<211> LENGTH, 537 
<212> TYPE, PRT 
35 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 5 
Met Lys Asn Met Ala Lys Leu Leu Asn 
1 5 
Phe Thr Ile Ala Phe Leu Ser Phe Ala 
20 25 
-continued 
Lys Thr Ile Phe Cys Ile Leu 
10 15 
Lys Leu Leu Ser Ser Tyr Leu 
30 
Ser Met Pro Phe Pro Leu Lys Tyr Met Ser Leu Ile Val Pro Leu Leu 
35 40 45 
Pro Leu Ile Ile Asn Phe Leu Tyr Val Lys Pro Gln Asn Asn Leu Pro 
50 55 60 
Pro Gly Pro Thr Ala Val Pro Ile Phe Gly Asn Trp Leu Gln Val Gly 
65 70 75 80 
Asn Asp Leu Asn His Gln Leu Leu Ala Thr Met Ser Gln Thr Tyr Gly 
85 90 95 
Pro Ile Phe Leu Leu Lys Leu Gly Ser Lys Asn Leu Ala Val Val Ser 
100 105 110 
Asn Pro Glu Leu Ala Asp Gln Val Leu His Thr Gln Gly Val Glu Phe 
115 120 125 
Gly Ser Arg Pro Arg Asn Val Val Phe Asp Ile Phe Thr Gly Asn Gly 
130 135 140 
Gln Asp Met Val Phe Thr Ile Tyr Gly Asp His Trp Arg Lys Met Arg 
145 150 155 160 
Arg Ile Met Thr Leu Pro Phe Phe Thr Asn Lys Val Val His Gln Tyr 
165 170 175 
Ser Asp Met Trp Glu Asn Glu Met Asp Leu Val Val Asn Asp Leu Lys 
180 185 190 
Lys Asn Glu Lys Val Lys Tyr Glu Gly Ile Val Ile Arg Lys Arg Leu 
195 200 205 
Gln Leu Met Leu Tyr Asn Ile Met Tyr Arg Met Met Phe Asp Ala Lys 
210 215 220 
Phe Glu Ser Gln Asn Asp Pro Leu Phe Ile Glu Ala Thr Lys Phe Asn 
225 230 235 240 
Ser Glu Arg Ser Arg Leu Ala Gln Ser Phe Asp Tyr Asn Tyr Gly Asp 
245 250 255 
Phe Ile Pro Leu Leu Arg Pro Phe Leu Arg Gly Tyr Leu Asn Lys Cys 
260 265 270 
Lys Asp Leu Gln Thr Arg Arg Leu Ala Phe Phe Asn Asn Tyr Phe Val 
275 280 285 
Glu Lys Arg Arg Lys Ile Met Asp Glu Asn Gly Glu Lys His Lys Ile 
290 295 300 
Ser Cys Ala Ile Asp His Ile Ile Asp Ala Glu Met Lys Gly Glu Ile 
305 310 315 320 
Asn Glu Gln Asn Val Leu Tyr Ile Val Glu Asn Ile Asn Val Ala Ala 
325 330 335 
Ile Glu Thr Thr Leu Trp Ser Met Glu Trp Ala Ile Ala Glu Leu Val 
340 345 350 
Asn His Pro Ile Val Gln Gln Lys Ile Arg Asp Glu Ile Ser Thr Val 
355 360 365 
Leu Lys Gly Arg Ser Val Thr Glu Ser Asn Leu His Glu Leu Pro Tyr 
370 375 380 
36 
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37 
-continued 
Leu Leu Ala Thr Val Asn Glu Thr Leu Arg Leu His Thr Pro Ile Pro 
385 390 395 400 
Leu Leu Val Pro His Met Asn Leu Glu Glu Ala Lys Leu Gly Gly Tyr 
405 410 415 
Thr Ile Pro Lys Glu Thr Lys Val Val Val Asn Ala Trp Trp Leu Ala 
420 425 430 
Asn Asn Pro Ala Trp Trp Lys Asn Pro Asn Glu Phe Arg Pro Glu Arg 
435 440 445 
Phe Leu Glu Glu Asp Ser Ser Thr Glu Ala Ala Val Ala Gly Gly Lys 
450 455 460 
Val Asp Phe Arg Tyr Leu Pro Phe Gly Met Gly Arg Arg Ser Cys Pro 
465 470 475 480 
Gly Ile Ile Leu Ala Leu Pro Ile Leu Gly Leu Val Ile Ala Lys Leu 
485 490 495 
Val Ser Asn Phe Glu Met Gln Gly Pro Pro Gly Val Glu Lys Val Asp 
500 505 510 
Thr Ser Glu Arg Gly Gly Gln Phe Ser Leu His Ile Ala Lys His Ser 
515 520 525 
Thr Val Val Phe Lys Pro Ile Ala Ala 
530 535 
<210> SEQ ID NO 6 
<211> LENGTH, 1745 
<212> TYPE, DNA 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 
cctctagcta atgaaaaaca tggccaaact tctcaacaag accatctttt gcattctctt 
tacaattgca tttctttcat ttgccaagtt actgtcctcc tacctatcta tgcctttccc 
tcttaagtac atgtcactta ttgtcccttt acttcccctt ataatcaact tcctctatgt 
taagccccaa aacaacctcc cacctggtcc aacagcagtc ccaatatttg gtaattggct 
tcaagttggc aatgacttga accatcaact ccttgccacc atgtcacaaa cctacggtcc 
tatattttta ctcaaacttg gttcaaaaaa cctagctgtg gtatcaaacc cagagctagc 
tgaccaagtt ctacacacac aaggggtcga gtttgggtcc cgtccacgta acgttgtctt 
cgacatattt actggtaatg gacaagacat ggtgttcacc atttatggtg accattggcg 
aaaaatgagg cgtattatga cgcttccatt tttcactaac aaagtggtgc accaatatag 
tgatatgtgg gagaatgaga tggacttagt tgttaatgac ttgaagaaga atgaaaaagt 
gaaatatgag ggaattgtga ttaggaaacg attgcagctg atgctgtata acatcatgta 
tcgaatgatg tttgatgcca aatttgagtc ccaaaatgat cctttgttca ttgaggcaac 
aaagtttaat tcagagagaa gcagattagc tcagagcttt gactacaatt atggtgattt 
tatcccttta cttagaccat tcttgagagg gtaccttaac aagtgtaaag acttacaaac 
aaggagactt gcattcttca acaattattt tgtagagaaa agaaggaaaa taatggatga 
aaatggagaa aagcataaga taagctgtgc tattgatcac attatagatg ccgaaatgaa 
aggagaaata aatgagcaaa atgtactcta tattgtggag aatatcaatg ttgcagcaat 
tgaaacaact ctatggtcca tggaatgggc catagctgaa cttgtaaatc atcccattgt 
tcaacagaag attagggatg aaatctcaac agtcctcaaa ggcagatcag tcacagaatc 
aaacctccat gagctgcctt acttgctagc aacagtaaat gaaacattaa gactccacac 
accaatacct ttacttgtac cccatatgaa ccttgaagaa gcaaagttag gtggttacac 
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39 
-continued 
tattcctaaa gaaactaagg 
gtggaaaaac ccgaatgaat 
ggcagctgtt gctggtggca 
gagctgcccc ggaatcatcc 
gtcaaatttt gaaatgcagg 
agggcagttt agcttgcaca 
ataataatat gcttaagcta 
tactaagtta ctcgataaag 
aaaaa 
<210> SEQ ID NO 7 
<211> LENGTH, 534 
<212> TYPE, PRT 
tggttgtgaa 
tccggcccga 
aggtagattt 
ttgcactgcc 
gtccaccagg 
ttgcaaaaca 
tccttgtttt 
atttcaatga 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 7 
tgcgtggtgg ctggctaaca accctgcttg 
gaggtttctt gaggaggata gtagcacaga 
caggtactta ccattcggta tggggaggcg 
aattctgggg cttgtcatag ccaaactggt 
tgtggaaaag gttgatacaa gtgaaagagg 
ttccacggtt gtcttcaagc ctattgctgc 
aattatattt gtcttaccag aaagcaaaac 
atattacagt ttttgttaaa aaaaaaaaaa 
Met Ala Lys Leu Leu Asn Asn Thr Ile Phe Cys Ile Leu Phe Ser Ile 
1 5 10 15 
Val Phe Leu Ser Phe Ala Lys Leu Leu Ser Ser Tyr Leu Ser Ile Pro 
20 25 30 
Phe Pro Leu Glu Tyr Ile Ser Leu Ile Val Leu Leu Leu Pro Leu Ile 
35 40 45 
Ile Asn Phe Leu Cys Val Lys Pro Gln Asn Asn Leu Pro Pro Gly Pro 
50 55 60 
Thr Ala Val Pro Ile Phe Gly Asn Trp Leu Gln Val Gly Asn Asp Leu 
65 70 75 80 
Asn His Gln Leu Leu Ala Thr Met Ser Gln Thr Tyr Gly Pro Ile Phe 
85 90 95 
Leu Leu Lys Leu Gly Ser Lys Asn Leu Ala Val Val Ser Asn Pro Glu 
100 105 110 
Leu Ala Asn Gln Val Leu His Thr Gln Gly Val Glu Phe Gly Ser Arg 
115 120 125 
Pro Arg Asn Val Val Phe Asp Ile Phe Thr Gly Asn Gly Gln Asp Met 
130 135 140 
Val Phe Thr Ile Tyr Gly Asp His Trp Arg Lys Met Arg Arg Ile Met 
145 150 155 160 
Thr Leu Pro Phe Phe Thr Asn Lys Val Val His Gln Tyr Ser Asp Met 
165 170 175 
Trp Glu Asn Glu Met Asp Leu Val Val Asp Asp Leu Lys Lys Asn Glu 
180 185 190 
Lys Val Lys Tyr Asp Gly Ile Val Ile Arg Lys Arg Leu Gln Leu Met 
195 200 205 
Leu Tyr Asn Ile Met Tyr Arg Met Met Phe Asp Ala Lys Phe Glu Ser 
210 215 220 
Gln Asp Asp Pro Leu Phe Ile Glu Ala Thr Lys Phe Asn Ser Glu Arg 
225 230 235 240 
Ser Arg Leu Ala Gln Ser Phe Asp Tyr Asn Tyr Gly Asp Phe Ile Pro 
245 250 255 
Leu Leu Arg Pro Phe Leu Lys Gly Tyr Leu Asn Lys Cys Lys Asp Leu 
260 265 270 
Gln Thr Arg Arg Leu Ala Phe Phe Asn Asn Tyr Phe Val Gly Lys Arg 
275 280 285 
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41 
-continued 
Arg Lys Ile Met Gly Glu Asn Gly Glu Lys His Lys Ile Cys Cys Ala 
290 295 300 
Ile Asp His Ile Ile Asp Ala Glu Met Lys Gly Glu Ile Ser Glu Gln 
305 310 315 320 
Asn Val Leu Tyr Ile Val Glu Asn Ile Asn Val Ala Ala Ile Glu Thr 
325 330 335 
Thr Leu Trp Ser Met Glu Trp Ala Ile Ala Glu Leu Val Asn His Pro 
340 345 350 
Ile Val Gln Gln Lys Ile Arg Asp Glu Ile Ser Thr Val Leu Lys Gly 
355 360 365 
Lys Ser Val Lys Glu Ser Asn Leu His Glu Leu Pro Tyr Leu Leu Ala 
370 375 380 
Thr Val Asn Glu Thr Leu Arg Leu His Thr Pro Ile Pro Leu Leu Val 
385 390 395 400 
Pro His Met Asn Leu Glu Glu Ala Lys Leu Gly Gly Tyr Thr Ile Pro 
405 410 415 
Lys Glu Thr Lys Val Val Val Asn Ala Trp Trp Leu Ala Asn Asn Pro 
420 425 430 
Ala Trp Trp Lys Asn Gln Asn Glu Phe Arg Pro Glu Arg Phe Leu Glu 
435 440 445 
Glu Asp Ser Ser Thr Glu Ala Ala Val Ala Gly Gly Lys Val Asp Phe 
450 455 460 
Arg Tyr Leu Pro Phe Gly Met Gly Arg Arg Ser Cys Pro Gly Ile Ile 
465 470 475 480 
Leu Ala Leu Pro Ile Leu Gly Leu Val Ile Ala Lys Leu Val Ser Asn 
485 490 495 
Phe Glu Met Gln Ala Pro Pro Gly Val Gly Lys Val Asp Thr Ser Glu 
500 505 510 
Lys Gly Gly Gln Phe Ser Leu His Ile Ala Lys His Ser Thr Val Val 
515 520 525 
Phe Lys Pro Ile Ala Ala 
530 
<210> SEQ ID NO 8 
<211> LENGTH, 1693 
<212> TYPE, DNA 
<213> ORGANISM, Nicotiana tabacum 
<400> SEQUENCE, 8 
cctctagcta attaaaaaca tggccaaact 
ttcaattgta tttctttcat ttgccaaatt 
tcttgagtac atttcactta ttgtcctttt 
taagccccaa aacaacctcc cacctggtcc 
tcaagttggc aatgacttga accatcaact 
tatattttta ctcaaacttg gttcaaaaaa 
taaccaagtt ctacacacgc aaggggtcga 
tgatatattt actggtaatg gacaagacat 
aaaaatgagg cgtattatga cgcttccatt 
tgatatgtgg gagaatgaga tggacctagt 
gaaatatgac ggaattgtga ttaggaaacg 
tcgaatgatg tttgatgcca agtttgagtc 
tctcaacaac accatctttt 
actatcctcc tacctctcta 
acttccccta ataatcaact 
aacagcagtc ccaatttttg 
ccttgccacc atgtcacaaa 
cctagctgtg gtatcgaacc 
gtttgggtcc cgtccacgta 
ggtgttcacc atttatggtg 
tttcactaac aaagtggtgc 
tgttgatgac ttgaagaaga 
attgcagctg atgctatata 
ccaagatgat cctttgttca 
gcattctctt 
tacctttccc 
tcctctgtgt 
gtaattggct 
cctatggtcc 
ctgagctagc 
acgttgtctt 
accattggcg 
accaatatag 
atgaaaaagt 
acattatgta 
ttgaggcaac 
42 
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43 
-continued 
aaagtttaat tcagagagaa 
tatccctttg cttagaccat 
aaggagactt gcattcttca 
aaatggagaa aaacacaaga 
aggagaaata agtgagcaaa 
tgaaacaact ctatggtcca 
tcaacagaag attagggatg 
aaacctacat gagctgcctt 
accaatacct ttacttgtac 
tattcctaaa gaaactaagg 
gtggaaaaac cagaacgaat 
ggcagctgtt gctggtggca 
gagctgcccc ggaatcatcc 
gtcaaatttt gaaatgcagg 
agggcagttt agcttgcaca 
ataatattac agtttttgtt 
aaaaaaaaaa aaa 
<210> SEQ ID NO 9 
<211> LENGTH, 519 
<212> TYPE, PRT 
gcagattagc tcagagcttt gactacaatt 
tcttgaaagg gtaccttaac aagtgcaaag 
acaattattt tgtagggaaa agaaggaaaa 
tatgttgtgc tattgatcac attatagatg 
atgtactcta tattgtggag aatatcaatg 
tggaatgggc catagctgag cttgtaaatc 
aaatctcaac agtcctcaaa ggaaagtcag 
acttgctagc aacagtaaat gaaacattaa 
cacatatgaa ccttgaagaa gcaaagctag 
tggttgtgaa tgcatggtgg ctggctaaca 
tccggcccga gcggtttctc gaggaggata 
aggttgattt caggtacttg cccttcggta 
ttgcactgcc aattctgggg cttgtcatag 
ctcctccagg tgtaggaaaa gttgatacaa 
ttgcaaaaca ttccacggtt gtcttcaagc 
actctataaa gatttcaatg aatattacag 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 9 
Met Tyr His Leu Leu Ser Pro Ile Glu Ala Ile Val Gly Leu 
1 5 10 
Phe Ala Phe Leu Leu Tyr Leu Leu Trp Thr Lys Lys Gln Ser 
20 25 30 
atggtgattt 
acttacaaac 
taatgggtga 
ctgaaatgaa 
ttgcagcaat 
atcccattgt 
tcaaagaatc 
gactccacac 
gtggttacac 
accctgcctg 
gtagcacaga 
tggggaggcg 
ccaaactggt 
gtgagaaagg 
ctattgctgc 
tttttgttaa 
Val Thr 
15 
Lys Ile 
Leu Asn Pro Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly 
35 40 45 
His Leu Phe Tyr Phe Asn Asn Asn Gly Asp Asp Asp Arg His Phe Ser 
50 55 60 
Gln Lys Leu Gly Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe 
65 70 75 80 
Arg Leu Gly Phe Arg Arg Phe Leu Ala Val Ser Ser Tyr Glu Ala Met 
85 90 95 
Lys Glu Cys Phe Ser Thr Asn Asp Ile His Phe Ala Asp Arg Pro Ala 
100 105 110 
Leu Leu Tyr Gly Glu Tyr Leu Cys Tyr Asn Asn Ala Met Leu Ala Val 
115 120 125 
Ala Lys Tyr Gly Pro Tyr Trp Lys Lys Asn Arg Lys Leu Val Asn Gln 
130 135 140 
Glu Leu Leu Ser Val Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe 
145 150 155 160 
Ser Ile Val Gln Lys Asn Ile Lys Gln Leu Tyr Asn Cys Asp Ser Pro 
165 170 175 
Met Val Lys Ile Asn Leu Ser Asp Trp Ile Asp Lys Leu Thr Phe Asp 
180 185 190 
44 
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45 
-continued 
Ile Ile Leu Lys Met Val Val Gly Lys Thr Tyr Asn Asn Gly His Gly 
195 200 205 
Glu Ile Leu Lys Ala Ala Phe Gln Lys Phe Met Val Gln Ala Met Glu 
210 215 220 
Ile Glu Leu Tyr Asp Val Phe His Ile Pro Phe Phe Lys Trp Leu Asp 
225 230 235 240 
Leu Thr Gly Asn Ile Lys Ala Met Lys Gln Thr Phe Lys Asp Ile Asp 
245 250 255 
Asn Ile Ile Gln Gly Trp Leu Asp Glu His Ile Lys Lys Arg Glu Thr 
260 265 270 
Lys Asp Val Gly Gly Glu Asn Glu Gln Asp Phe Ile Asp Val Leu Leu 
275 280 285 
Ser Lys Arg Ser Asn Glu His Leu Gly Asp Gly Tyr Ser His Asp Thr 
290 295 300 
Thr Ile Lys Ala Thr Val Phe Thr Leu Val Leu Asp Ala Thr Asp Thr 
305 310 315 320 
Leu Ala Leu His Ile Lys Trp Val Met Ala Leu Met Ile Asn Asn Lys 
325 330 335 
Asn Val Met Lys Lys Ala Gln Glu Glu Met Asp Thr Ile Val Gly Arg 
340 345 350 
Asp Arg Trp Val Glu Glu Asn Asp Ile Lys Asn Leu Val Tyr Leu Gln 
355 360 365 
Ala Ile Val Lys Glu Val Leu Arg Leu His Pro Pro Ala Pro Leu Ser 
370 375 380 
Val Gln His Leu Ser Val Lys Asp Cys Val Val Asn Gly Tyr His Ile 
385 390 395 400 
Pro Lys Gly Thr Ala Leu Leu Thr Asn Ile Met Lys Leu Gln Arg Asp 
405 410 415 
Pro Gln Ile Trp Val Asp Pro Asp Thr Phe Asp Pro Glu Arg Phe Leu 
420 425 430 
Thr Thr Asn Ala Ala Ile Asp Tyr Arg Gly Gln His Tyr Glu Leu Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ala Cys Pro Ala Met Asn Tyr Ser Leu 
450 455 460 
Gln Val Glu His Leu Ser Ile Ala His Leu Ile Gln Gly Phe Asn Phe 
465 470 475 480 
Ala Thr Thr Thr Asn Glu Pro Leu Asp Met Lys Gln Gly Val Gly Leu 
485 490 495 
Thr Leu Pro Lys Lys Thr Asp Val Glu Val Leu Ile Thr Pro Arg Leu 
500 505 510 
Pro Pro Thr Leu Tyr Gln Tyr 
515 
<210> SEQ ID NO 10 
<211> LENGTH, 1578 
<212> TYPE, DNA 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 10 
atgtatcatc ttctttctcc catagaagcc attgtaggac ttgtaacctt tgcatttcta 60 
ctctacttgc tatggacaaa aaaacaatca aaaatcttaa acccactgcc tccaaaaatc 120 
ccaggtggat ggccagtaat cggccatctc ttttatttca acaacaatgg cgatgatgac 180 
cgccattttt ctcaaaaact cggagactta gctgacaaat atggtcccgt cttcacattc 240 
46 
US 10,184,118 B2 
47 
-continued 
cggttagggt ttcgccgttt cttggcggtg agtagttatg aagctatgaa agaatgcttc 
tctaccaatg atatccattt cgccgatcgg ccagctttac tttacggaga atacctttgc 
tataacaatg ccatgcttgc tgttgccaaa tatggccctt actggaaaaa aaatcgaaag 
ctagtcaatc aagaacttct ctccgttagt cggctcgaaa aattcaaaca tgttagattt 
tctatagttc agaaaaatat taaacaattg tataattgtg attcaccaat ggtgaagata 
aaccttagtg attggataga taaattgaca ttcgacatca ttttgaaaat ggttgttggg 
aagacctata ataatggaca tggagaaata ctcaaagcag cttttcagaa gttcatggtt 
caagctatgg agattgagct ctatgatgtt tttcacattc catttttcaa gtggttggat 
cttacaggga atattaaggc tatgaaacaa actttcaaag acattgataa tattatccaa 
ggttggttag atgagcacat taagaagaga gaaacaaagg atgttggagg tgaaaatgaa 
caagatttta ttgatgtgct gctttccaag aggagcaacg aacatcttgg cgatggttac 
tctcatgaca ccaccatcaa agcaacagta ttcactttgg tcttggatgc aacagacaca 
cttgcacttc atataaagtg ggtaatggcg ttaatgataa acaataagaa tgtcatgaag 
aaagcacaag aagagatgga caccattgtt ggtagagata gatgggtaga agagaatgat 
atcaagaatt tggtgtatct tcaagcaatt gttaaagaag tattacgatt acatccacct 
gcacctttgt cagtacaaca cctatccgta aaagattgtg ttgtcaatgg ataccatatt 
cctaagggga ctgcactact tacaaatatt atgaaacttc aacgagaccc acaaatatgg 
gtagatcctg atacattcga tccagaaaga ttcttgacga ctaatgctgc aattgactat 
cgcgggcagc actatgagtt gatcccgttt ggatcaggga gacgagcttg tcccgcgatg 
aattactcat tgcaagtgga acacctttca attgctcatt tgatccaggg tttcaatttt 
gcaactacga ctaacgagcc tttggatatg aaacaaggcg tgggtctaac tttacctaag 
aagacagatg ttgaagtgct aattacacct cgccttcctc ctacgcttta tcaatattaa 
tatgttttgt tgttgtga 
<210> SEQ ID NO 11 
<211> LENGTH, 509 
<212> TYPE, PRT 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 11 
Met Glu Gly Thr Asn Leu Thr Thr Tyr Ala Ala Val Phe Leu Gly Thr 
1 5 10 15 
Leu Phe Leu Leu Leu Leu Ser Lys Phe Leu Arg Gln Arg Lys Leu Asn 
20 25 30 
Leu Pro Pro Gly Pro Lys Pro Trp Pro Ile Ile Gly Asn Leu Asn Leu 
35 40 45 
Ile Gly Asn Leu Pro His Arg Ser Ile His Glu Leu Ser Leu Lys Tyr 
50 55 60 
Gly Pro Ile Met Gln Leu Gln Phe Gly Thr Phe Pro Val Val Val Gly 
65 70 75 80 
Ser Ser Val Glu Met Ala Lys Val Phe Leu Lys Ser Met Asp Ile Asn 
85 90 95 
Phe Val Gly Arg Pro Lys Thr Ala Ala Gly Lys Tyr Thr Thr Tyr Asn 
100 105 110 
Tyr Ser Asp Ile Thr Trp Ser Pro Tyr Gly Pro Tyr Trp Arg Gln Ala 
115 120 125 
48 
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1380 
1440 
1500 
1560 
1578 
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-continued 
Arg Arg Met Cys Leu Met Glu Leu Phe Ser Thr Lys Arg Leu Asp Ser 
130 135 140 
Tyr Glu Tyr Ile Arg Ala Glu Glu Leu His Ser Leu Leu His Asn Leu 
145 150 155 160 
Asn Lys Ile Ser Gly Lys Pro Ile Val Leu Lys Asp Tyr Leu Thr Thr 
165 170 175 
Leu Ser Leu Asn Val Ile Ser Arg Met Val Leu Gly Lys Arg Tyr Leu 
180 185 190 
Asp Glu Ser Glu Asn Ser Ile Val Thr Pro Glu Glu Phe Lys Lys Met 
195 200 205 
Leu Asp Glu Leu Phe Leu Leu Asn Gly Val Leu Asn Ile Gly Asp Ser 
210 215 220 
Ile Pro Trp Ile Asp Phe Met Asp Leu Gln Gly Tyr Val Lys Arg Met 
225 230 235 240 
Lys Phe Val Ser Lys Lys Phe Asp Lys Phe Leu Glu His Val Ile Asp 
245 250 255 
Glu His Asn Val Arg Arg Asn Gly Val Glu Asn Tyr Ile Ala Lys Asp 
260 265 270 
Met Val Asp Val Leu Leu Gln Leu Ala Asp Asp Pro Thr Leu Glu Val 
275 280 285 
Lys Leu Glu Arg His Gly Val Lys Ala Phe Thr Gln Asp Met Leu Ala 
290 295 300 
Gly Gly Thr Glu Ser Ser Ala Val Thr Val Glu Trp Ala Ile Ser Glu 
305 310 315 320 
Leu Leu Lys Lys Pro Glu Ile Phe Lys Lys Ala Thr Glu Glu Leu Asp 
325 330 335 
Arg Val Ile Gly Gln Asn Arg Trp Val Gln Glu Lys Asp Ile Pro Asn 
340 345 350 
Leu Pro Tyr Ile Glu Ala Ile Val Lys Glu Thr Met Arg Leu His Pro 
355 360 365 
Val Ala Pro Met Leu Val Pro Arg Glu Cys Arg Glu Asp Cys Lys Val 
370 375 380 
Ala Gly Tyr Asp Val Lys Lys Gly Thr Arg Val Leu Val Ser Val Trp 
385 390 395 400 
Thr Ile Gly Arg Asp Pro Thr Leu Trp Asp Glu Pro Glu Ala Phe Lys 
405 410 415 
Pro Glu Arg Phe His Glu Lys Ser Ile Asp Val Lys Gly His Asp Phe 
420 425 430 
Glu Leu Leu Pro Phe Gly Ala Gly Arg Arg Met Cys Pro Gly Tyr Asn 
435 440 445 
Leu Gly Leu Lys Val Ile Gln Ala Ser Leu Ala Asn Leu Ile His Gly 
450 455 460 
Phe Asn Trp Ser Leu Pro Asp Asn Met Thr Pro Glu Asp Leu Asp Met 
465 470 475 480 
Asp Glu Ile Phe Gly Leu Ser Thr Pro Lys Lys Phe Pro Leu Ala Thr 
485 490 495 
Val Ile Glu Pro Arg Leu Ser Pro Lys Leu Tyr Ser Val 
500 505 
<210> SEQ ID NO 12 
<211> LENGTH, 1530 
<212> TYPE, DNA 
<213> ORGANISM: Nicotiana tabacum 
50 
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-continued 
<400> SEQUENCE, 12 
atggaaggta caaacttgac tacatatgca gcagtatttc ttggtactct gtttcttttg 
ctcctttcca aatttcttcg ccaaagaaaa ctcaacttac ctccaggccc aaaaccatgg 
ccgatcatcg gaaacttaaa ccttatcggc aatcttcctc atcgctcaat ccacgaactt 
tcactcaagt acgggccaat tatgcaactc caattcggga ctttccccgt tgttgttggc 
tcttccgtcg aaatggccaa ggttttcctc aaatcaatgg atattaactt tgtaggcagg 
cctaaaacgg ccgccgggaa gtacacaact tacaattatt cagatattac atggtctcct 
tatggaccat attggcgcca ggcacgtaga atgtgcctaa tggaattatt cagcacgaaa 
cgtctcgatt catacgagta tattcgggct gaggagttgc attctctgct ccataatttg 
aataaaatat cagggaaacc aattgtgctg aaagattatt tgacgacgtt gagtttaaat 
gttattagca ggatggtact ggggaagagg tatttggacg aatccgagaa ctcgattgtg 
actcctgagg aatttaagaa gatgttggac gagctgttct tgctaaatgg tgtacttaat 
attggagatt caattccctg gattgatttc atggacttac aaggttatgt taagaggatg 
aaatttgtga gcaagaaatt cgacaagttt ttggagcatg ttatcgatga gcataacgtt 
aggagaaatg gagtggagaa ttacattgct aaggacatgg ttgatgttct gttgcagctt 
gctgatgatc cgacgttgga agttaagctg gagagacatg gagtcaaagc attcactcag 
gatatgcttg ctggtggaac cgagagttca gcagtgacag tggagtgggc aatttcggag 
ctgctaaaga agccagagat tttcaaaaag gctacagaag aattggatcg agtaattggg 
cagaatagat gggtacaaga aaaagacatt ccaaatcttc cttacataga ggcaatagtc 
aaagagacta tgcgactgca ccccgtggca ccaatgttgg tgccacggga gtgtcgagaa 
gactgtaagg tagcaggcta cgacgttaag aaaggaacca gggtccttgt gagcgtatgg 
actattggaa gagaccctac attgtgggac gagcctgagg cgttcaagcc ggagaggttc 
cacgaaaagt ccattgatgt taaaggacat gattttgagc ttttgccatt tggagctggg 
agaaggatgt gcccgggtta taacttgggg cttaaggtga ttcaagctag cttagctaat 
cttatacatg gatttaactg gtcattgcct gataatatga ctcctgagga cctcgacatg 
gatgagattt ttgggctctc cacacctaaa aagtttccac ttgctactgt gattgagcca 
agactttcac caaaacttta ctctgtttga 
<210> SEQ ID NO 13 
<211> LENGTH, 36 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Derived from Nicotiana tabacum p450 gene 
<400> SEQUENCE, 13 
ggcggagaat ttgtcctgga atgtcatttg gtttag 
<210> SEQ ID NO 14 
<211> LENGTH, 23 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Derived from Nicotiana tabacum p450 gene 
<400> SEQUENCE, 14 
gtacaatagt gaggttgaca atg 
52 
60 
120 
180 
240 
300 
360 
420 
480 
540 
600 
660 
720 
780 
840 
900 
960 
1020 
1080 
1140 
1200 
1260 
1320 
1380 
1440 
1500 
1530 
36 
23 
<210> SEQ ID NO 15 
<211> LENGTH, 18 
<212> TYPE, DNA 
53 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
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-continued 
<223> OTHER INFORMATION, Derived from Nicotiana tabacum p450 gene 
<400> SEQUENCE, 15 
ggtggttgtg aatgcatg 
<210> SEQ ID NO 16 
<211> LENGTH, 25 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Derived from Nicotiana tabacum p450 gene 
<400> SEQUENCE, 16 
ttatgcagca ataggcttga agaca 
<210> SEQ ID NO 17 
<211> LENGTH, 33 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Derived from Nicotiana tabacum p450 gene 
<400> SEQUENCE, 17 
gggggatcca tgcaattctt cagcttggtt tee 
<210> SEQ ID NO 18 
<211> LENGTH, 33 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Derived from Nicotiana tabacum p450 gene 
<400> SEQUENCE, 18 
ggggaattct tactctcgag aaggttgata agg 
<210> SEQ ID NO 19 
<211> LENGTH, 30 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Derived from Nicotiana tabacum p450 gene 
<400> SEQUENCE, 19 
cccggatcca tgtatcatct tctttctccc 
<210> SEQ ID NO 20 
<211> LENGTH, 33 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Derived from Nicotiana tabacum p450 gene 
<400> SEQUENCE, 20 
ggggaattct caatattgat aaagcgtagg agg 
<210> SEQ ID NO 21 
<211> LENGTH, 33 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Derived from Nicotiana tabacum p450 gene 
54 
18 
25 
33 
33 
30 
33 
55 
<400> SEQUENCE, 21 
cccggatcca tgcaatcctt cagcttggtt tee 
<210> SEQ ID NO 22 
<211> LENGTH, 33 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, Derived from Nicotiana tabacum p450 gene 
<400> SEQUENCE, 22 
ggggagctct cactcgcaag aagattgata agg 
<210> SEQ ID NO 23 
<211> LENGTH, 75 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Derived from Nicotiana tabacum p450 gene 
<400> SEQUENCE, 23 
33 
33 
gccattatcg gcgcaatact aatctccaaa ctccgcggta aaaaattcaa gctcccacct 60 
ggtccaacag cagtc 75 
<210> SEQ ID NO 24 
<211> LENGTH, 75 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Derived from Nicotiana tabacum p450 gene 
<400> SEQUENCE, 24 
gggggatcca tggacctcct cctcatagaa aaaaccctcg tcgccttatt cgccgccatt 60 
atcggcgcaa tacta 75 
<210> SEQ ID NO 25 
<211> LENGTH, 33 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Derived from Nicotiana tabacum p450 gene 
<400> SEQUENCE, 25 
ggggagctct tatgcagcaa taggcttgaa gac 
<210> SEQ ID NO 26 
<211> LENGTH, 7 
<212> TYPE, PRT 
<213> ORGANISM: Nicotiana tabacum 
<220> FEATURE, 
<223> OTHER INFORMATION, Nicotiana tabacum p450 protein 
<220> FEATURE, 
<221> NAME/KEY, VARIANT 
<222> LOCATION, (7) .. (7) 
<223> OTHER INFORMATION, Xaa 
<400> SEQUENCE, 26 
Lys Glu Thr Leu Arg Leu Xaa 
1 5 
<210> SEQ ID NO 27 
<211> LENGTH, 11 
<212> TYPE, PRT 
any amino acid 
<213> ORGANISM: Nicotiana tabacum 
33 
56 
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-continued 
<220> FEATURE, 
<223> OTHER INFORMATION, Nicotiana tabacum p450 protein 
<220> FEATURE, 
<221> NAME/KEY, VARIANT 
<222> LOCATION, (4) .. (4) 
<223> OTHER INFORMATION, Xaa any amino acid 
<220> FEATURE, 
<221> NAME/KEY, VARIANT 
<222> LOCATION, (8) .. (8) 
<223> OTHER INFORMATION, Xaa any amino acid 
<400> SEQUENCE, 27 
Pro Phe Gly Xaa Gly Arg Arg Xaa Cys Pro Ala 
1 5 10 
<210> SEQ ID NO 28 
<211> LENGTH, 11 
<212> TYPE, PRT 
<213> ORGANISM: Nicotiana tabacum 
<220> FEATURE, 
<223> OTHER INFORMATION, Nicotiana tabacum p450 protein 
<220> FEATURE, 
<221> NAME/KEY, VARIANT 
<222> LOCATION, (4) .. (4) 
<223> OTHER INFORMATION, Xaa any amino acid 
<220> FEATURE, 
<221> NAME/KEY, VARIANT 
<222> LOCATION, (8) .. (8) 
<223> OTHER INFORMATION, Xaa any amino acid 
<400> SEQUENCE, 28 
Pro Phe Gly Xaa Gly Arg Arg Xaa Cys Pro Gly 
1 5 
<210> SEQ ID NO 29 
<211> LENGTH, 
<212> TYPE, PRT 
<213> ORGANISM: Nicotiana tabacum 
<220> FEATURE, 
10 
<223> OTHER INFORMATION, Nicotiana tabacum p450 protein 
<220> FEATURE, 
<221> NAME/KEY, VARIANT 
<222> LOCATION, (2) .. (2) 
<223> OTHER INFORMATION, Xaa 
<400> SEQUENCE, 29 
Phe Xaa Pro Glu Arg Phe 
1 5 
<210> SEQ ID NO 30 
<211> LENGTH, 20 
<212> TYPE, PRT 
any amino acid 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Derived from Nicotiana tabacum p450 protein 
<400> SEQUENCE, 30 
Ala Ala Arg Gly Ala Arg Ala Cys Ile Tyr Thr Ile Met Gly Ile Tyr 
1 5 10 15 
Thr Ile Cys Ala 
20 
<210> SEQ ID NO 31 
<211> LENGTH, 20 
<212> TYPE, PRT 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Derived from Nicotiana tabacum p450 protein 
58 
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-continued 
<400> SEQUENCE, 31 
Ala Ala Arg Gly Ala Arg Ala Cys Ile Tyr Thr Ile Met Gly Ile Tyr 
1 5 10 15 
Thr Ile Thr Ala 
20 
<210> SEQ ID NO 32 
<211> LENGTH, 20 
<212> TYPE, PRT 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Derived from Nicotiana tabacum p450 protein 
<400> SEQUENCE, 32 
Ala Ala Arg Gly Ala Arg Ala Cys Ile Tyr Thr Ile Met Gly Ile Tyr 
1 5 10 15 
Thr Ile Met Gly 
20 
<210> SEQ ID NO 33 
<211> LENGTH, 18 
<212> TYPE, PRT 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Derived from Nicotiana tabacum p450 protein 
<400> SEQUENCE, 33 
Thr Thr Tyr Ile Ile Ile Cys Cys Ile Gly Ala Arg Met Gly Ile Thr 
1 5 10 15 
Thr Tyr 
<210> SEQ ID NO 34 
<211> LENGTH, 18 
<212> TYPE, PRT 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Derived from Nicotiana tabacum p450 protein 
<400> SEQUENCE, 34 
Arg Ala Ala Ile Cys Lys Tyr Thr Cys Ile Gly Gly Ile Ile Ile Arg 
1 5 10 15 
Ala Ala 
<210> SEQ ID NO 35 
<211> LENGTH, 20 
<212> TYPE, PRT 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Derived from Nicotiana tabacum p450 protein 
<400> SEQUENCE, 35 
Gly Gly Ile Met Gly Ile Met Gly Ile Ile Ile Ile Thr Gly Tyr Cys 
1 5 10 15 
Cys Ile Gly Ser 
20 
<210> SEQ ID NO 36 
<211> LENGTH, 20 
<212> TYPE, PRT 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Derived from Nicotiana tabacum p450 protein 
60 
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-continued 
<400> SEQUENCE, 36 
Cys Lys Ile Cys Lys Ile Cys Cys Ile Ile Ile Ile Cys Cys Arg Ala 
1 5 10 15 
Ala Ile Gly Gly 
20 
<210> SEQ ID NO 37 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Derived from T7 bacteriophage promoter 
<400> SEQUENCE, 37 
gtaatacgac tcactatagg g 
<210> SEQ ID NO 38 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Derived from T3 bacteriophage promoter 
<400> SEQUENCE, 38 
caattaaccc tcactaaagg g 
<210> SEQ ID NO 39 
<211> LENGTH, 500 
<212> TYPE, PRT 
<213> ORGANISM, Mentha piperita 
<400> SEQUENCE, 39 
Met Glu Leu Gln Ile Ser Ser Ala Ile Ile Ile Leu Val Val Thr Tyr 
1 5 10 15 
Thr Ile Ser Leu Leu Ile Ile Lys Gln Trp Arg Lys Pro Lys Pro Gln 
20 25 30 
Glu Asn Leu Pro Pro Gly Pro Pro Lys Leu Pro Leu Ile Gly His Leu 
35 40 45 
His Leu Leu Trp Gly Lys Leu Pro Gln His Ala Leu Ala Ser Val Ala 
50 55 60 
Lys Gln Tyr Gly Pro Val Ala His Val Gln Leu Gly Glu Val Phe Ser 
65 70 75 80 
Val Val Leu Ser Ser Arg Glu Ala Thr Lys Glu Ala Met Lys Leu Val 
85 90 95 
Asp Pro Ala Cys Ala Asp Arg Phe Glu Ser Ile Gly Thr Lys Ile Met 
100 105 110 
Trp Tyr Asp Asn Asp Asp Ile Ile Phe Ser Pro Tyr Ser Val His Trp 
115 120 125 
Arg Gln Met Arg Lys Ile Cys Val Ser Glu Leu Leu Ser Ala Arg Asn 
130 135 140 
Val Arg Ser Phe Gly Phe Ile Arg Gln Asp Glu Val Ser Arg Leu Leu 
145 150 155 160 
Gly His Leu Arg Ser Ser Ala Ala Ala Gly Glu Ala Val Asp Leu Thr 
165 170 175 
Glu Arg Ile Ala Thr Leu Thr Cys Ser Ile Ile Cys Arg Ala Ala Phe 
180 185 190 
Gly Ser Val Ile Arg Asp His Glu Glu Leu Val Glu Leu Val Lys Asp 
195 200 205 
62 
21 
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Ala Leu Ser Met Ala Ser Gly Phe Glu Leu Ala Asp Met Phe Pro Ser 
210 215 220 
Ser Lys Leu Leu Asn Leu Leu Cys Trp Asn Lys Ser Lys Leu Trp Arg 
225 230 235 240 
Met Arg Arg Arg Val Asp Ala Ile Leu Glu Ala Ile Val Glu Glu His 
245 250 255 
Lys Leu Lys Lys Ser Gly Glu Phe Gly Gly Glu Asp Ile Ile Asp Val 
260 265 270 
Leu Phe Arg Met Gln Lys Asp Ser Gln Ile Lys Val Pro Ile Thr Thr 
275 280 285 
Asn Ala Ile Lys Ala Phe Ile Phe Asp Thr Phe Ser Ala Gly Thr Glu 
290 295 300 
Thr Ser Ser Thr Thr Thr Leu Trp Val Met Ala Glu Leu Met Arg Asn 
305 310 315 320 
Pro Glu Val Met Ala Lys Ala Gln Ala Glu Val Arg Ala Ala Leu Lys 
325 330 335 
Gly Lys Thr Asp Trp Asp Val Asp Asp Val Gln Glu Leu Lys Tyr Met 
340 345 350 
Lys Ser Val Val Lys Glu Thr Met Arg Met His Pro Pro Ile Pro Leu 
355 360 365 
Ile Pro Arg Ser Cys Arg Glu Glu Cys Glu Val Asn Gly Tyr Thr Ile 
370 375 380 
Pro Asn Lys Ala Arg Ile Met Ile Asn Val Trp Ser Met Gly Arg Asn 
385 390 395 400 
Pro Leu Tyr Trp Glu Lys Pro Glu Thr Phe Trp Pro Glu Arg Phe Asp 
405 410 415 
Gln Val Ser Arg Asp Phe Met Gly Asn Asp Phe Glu Phe Ile Pro Phe 
420 425 430 
Gly Ala Gly Arg Arg Ile Cys Pro Gly Leu Asn Phe Gly Leu Ala Asn 
435 440 445 
Val Glu Val Pro Leu Ala Gln Leu Leu Tyr His Phe Asp Trp Lys Leu 
450 455 460 
Ala Glu Gly Met Asn Pro Ser Asp Met Asp Met Ser Glu Ala Glu Gly 
465 470 475 480 
Leu Thr Gly Ile Arg Lys Asn Asn Leu Leu Leu Val Pro Thr Pro Tyr 
Asp Pro Ser Ser 
500 
485 490 495 
<210> SEQ ID NO 40 
<211> LENGTH, 496 
<212> TYPE, PRT 
<213> ORGANISM, Mentha spicata 
<400> SEQUENCE, 40 
Met Glu Leu Asp Leu Leu Ser Ala Ile Ile Ile Leu Val Ala Thr Tyr 
1 5 10 15 
Ile Val Ser Leu Leu Ile Asn Gln Trp Arg Lys Ser Lys Ser Gln Gln 
20 25 30 
Asn Leu Pro Pro Ser Pro Pro Lys Leu Pro Val Ile Gly His Leu His 
35 40 45 
Phe Leu Trp Gly Gly Leu Pro Gln His Val Phe Arg Ser Ile Ala Gln 
50 55 60 
64 
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Lys Tyr Gly Pro Val Ala His Val Gln Leu Gly Glu Val Tyr Ser Val 
65 70 75 80 
Val Leu Ser Ser Ala Glu Ala Ala Lys Gln Ala Met Lys Val Leu Asp 
85 90 95 
Pro Asn Phe Ala Asp Arg Phe Asp Gly Ile Gly Ser Arg Thr Met Trp 
100 105 110 
Tyr Asp Lys Asp Asp Ile Ile Phe Ser Pro Tyr Asn Asp His Trp Arg 
115 120 125 
Gln Met Arg Arg Ile Cys Val Thr Glu Leu Leu Ser Pro Lys Asn Val 
130 135 140 
Arg Ser Phe Gly Tyr Ile Arg Gln Glu Glu Ile Glu Arg Leu Ile Arg 
145 150 155 160 
Leu Leu Gly Ser Ser Gly Gly Ala Pro Val Asp Val Thr Glu Glu Val 
165 170 175 
Ser Lys Met Ser Cys Val Val Val Cys Arg Ala Ala Phe Gly Ser Val 
180 185 190 
Leu Lys Asp Gln Gly Ser Leu Ala Glu Leu Val Lys Glu Ser Leu Ala 
195 200 205 
Leu Ala Ser Gly Phe Glu Leu Ala Asp Leu Tyr Pro Ser Ser Trp Leu 
210 215 220 
Leu Asn Leu Leu Ser Leu Asn Lys Tyr Arg Leu Gln Arg Met Arg Arg 
225 230 235 240 
Arg Leu Asp His Ile Leu Asp Gly Phe Leu Glu Glu His Arg Glu Lys 
245 250 255 
Lys Ser Gly Glu Phe Gly Gly Glu Asp Ile Val Asp Val Leu Phe Arg 
260 265 270 
Met Gln Lys Gly Ser Asp Ile Lys Ile Pro Ile Thr Ser Asn Cys Ile 
275 280 285 
Lys Gly Phe Ile Phe Asp Thr Phe Ser Ala Gly Ala Glu Thr Ser Ser 
290 295 300 
Thr Thr Ile Ser Trp Ala Leu Ser Glu Leu Met Arg Asn Pro Ala Lys 
305 310 315 320 
Met Ala Lys Val Gln Ala Glu Val Arg Glu Ala Leu Lys Gly Lys Thr 
325 330 335 
Val Val Asp Leu Ser Glu Val Gln Glu Leu Lys Tyr Leu Arg Ser Val 
340 345 350 
Leu Lys Glu Thr Leu Arg Leu His Pro Pro Phe Pro Leu Ile Pro Arg 
355 360 365 
Gln Ser Arg Glu Glu Cys Glu Val Asn Gly Tyr Thr Ile Pro Ala Lys 
370 375 380 
Thr Arg Ile Phe Ile Asn Val Trp Ala Ile Gly Arg Asp Pro Gln Tyr 
385 390 395 400 
Trp Glu Asp Pro Asp Thr Phe Arg Pro Glu Arg Phe Asp Glu Val Ser 
405 410 415 
Arg Asp Phe Met Gly Asn Asp Phe Glu Phe Ile Pro Phe Gly Ala Gly 
420 425 430 
Arg Arg Ile Cys Pro Gly Leu His Phe Gly Leu Ala Asn Val Glu Ile 
435 440 445 
Pro Leu Ala Gln Leu Leu Tyr His Phe Asp Trp Lys Leu Pro Gln Gly 
450 455 460 
66 
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Met Thr Asp Ala Asp Leu Asp Met Thr Glu Thr Pro Gly Leu Ser Gly 
465 470 475 480 
Pro Lys Lys Lys Asn Val Cys Leu Val Pro Thr Leu Tyr Lys Ser Pro 
485 490 495 
<210> SEQ ID NO 41 
<211> LENGTH, 509 
<212> TYPE, PRT 
<213> ORGANISM: Nepeta racemosa 
<400> SEQUENCE, 41 
Met Val Ser Leu Ser Tyr Phe Leu Ile Ala Leu Leu Cys Thr Leu Pro 
1 5 10 15 
Phe Leu Leu Phe Leu Asn Lys Trp Arg Arg Ser Tyr Ser Gly Lys Thr 
20 25 30 
Pro Pro Pro Ser Pro Pro Lys Leu Pro Val Ile Gly Asn Leu His Gln 
35 40 45 
Leu Gly Leu Tyr Pro His Arg Tyr Leu Gln Ser Leu Ser Arg Arg Tyr 
50 55 60 
Gly Pro Leu Met Gln Leu His Phe Gly Ser Val Pro Val Leu Val Ala 
65 70 75 80 
Ser Ser Pro Glu Ala Ala Arg Glu Ile Met Lys Asn Gln Asp Ile Val 
85 90 95 
Phe Ser Asn Arg Pro Lys Met Ser Ile Ala Asn Arg Leu Phe Phe Asn 
100 105 110 
Asn Arg Asp Val Ala Phe Thr Gln Tyr Gly Glu Tyr Trp Arg Gln Ile 
115 120 125 
Arg Ser Ile Cys Val Leu Gln Leu Leu Ser Asn Lys Arg Val Gln Ser 
130 135 140 
Phe Arg Arg Val Arg Glu Glu Glu Thr Ser Ile Met Val Glu Lys Ile 
145 150 155 160 
Met Gln Leu Gly Ser Ser Ser Ser Thr Pro Val Asn Leu Ser Glu Leu 
165 170 175 
Leu Leu Ser Leu Thr Asn Asp Val Val Cys Arg Val Thr Leu Gly Lys 
180 185 190 
Lys Tyr Gly Gly Gly Asn Gly Ser Glu Glu Val Asp Lys Leu Lys Glu 
195 200 205 
Met Leu Thr Glu Ile Gln Asn Leu Met Gly Ile Ser Pro Val Trp Glu 
210 215 220 
Phe Ile Pro Trp Leu Asn Trp Thr Arg Arg Phe Asp Gly Val Asp Gln 
225 230 235 240 
Arg Val Asp Arg Ile Val Lys Ala Phe Asp Gly Phe Leu Glu Ser Val 
245 250 255 
Ile Gln Glu His Lys Glu Arg Asp Gly Asp Lys Asp Gly Asp Gly Asp 
260 265 270 
Gly Ala Leu Asp Phe Val Asp Ile Leu Leu Gln Phe Gln Arg Glu Asn 
275 280 285 
Lys Asn Arg Ser Pro Val Glu Asp Asp Thr Val Lys Ala Leu Ile Leu 
290 295 300 
Asp Met Phe Val Ala Gly Thr Asp Thr Thr Ala Thr Ala Leu Glu Trp 
305 310 315 320 
Ala Val Ala Glu Leu Ile Lys Asn Pro Arg Ala Met Lys Arg Leu Gln 
325 330 335 
Asn Glu Val Arg Glu Val Ala Gly Ser Lys Ala Glu Ile Glu Glu Glu 
340 345 350 
68 
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Asp Leu Glu Lys Met Pro Tyr Leu Lys Ala Ser Ile Lys Glu Ser Leu 
355 360 365 
Arg Leu His Val Pro Val Val Leu Leu Val Pro Arg Glu Ser Thr Arg 
370 375 380 
Asp Thr Asn Val Leu Gly Tyr Asp Ile Ala Ser Gly Thr Arg Val Leu 
385 390 395 400 
Ile Asn Ala Trp Ala Ile Ala Arg Asp Pro Ser Val Trp Glu Asn Pro 
405 410 415 
Glu Glu Phe Leu Pro Glu Arg Phe Leu Asp Ser Ser Ile Asp Tyr Lys 
420 425 430 
Gly Leu His Phe Glu Leu Leu Pro Phe Gly Ala Gly Arg Arg Gly Cys 
435 440 445 
Pro Gly Ala Thr Phe Ala Val Ala Ile Asp Glu Leu Ala Leu Ala Lys 
450 455 460 
Leu Val His Lys Phe Asp Phe Gly Leu Pro Asn Gly Ala Arg Met Glu 
465 470 475 480 
Glu Leu Asp Met Ser Glu Thr Ser Gly Met Thr Val His Lys Lys Ser 
485 490 495 
Pro Leu Leu Leu Leu Pro Ile Pro His His Ala Ala Pro 
500 505 
<210> SEQ ID NO 42 
<211> LENGTH, 471 
<212> TYPE, PRT 
<213> ORGANISM: Persea americana 
<400> SEQUENCE, 42 
Met Ala Ile Leu Val Ser Leu Leu Phe Leu Ala Ile Ala Leu Thr Phe 
1 5 10 15 
Phe Leu Leu Lys Leu Asn Glu Lys Arg Glu Lys Lys Pro Asn Leu Pro 
20 25 30 
Pro Ser Pro Pro Asn Leu Pro Ile Ile Gly Asn Leu His Gln Leu Gly 
35 40 45 
Asn Leu Pro His Arg Ser Leu Arg Ser Leu Ala Asn Glu Leu Gly Pro 
50 55 60 
Leu Ile Leu Leu His Leu Gly His Ile Pro Thr Leu Ile Val Ser Thr 
65 70 75 80 
Ala Glu Ile Ala Glu Glu Ile Leu Lys Thr His Asp Leu Ile Phe Ala 
85 90 95 
Ser Arg Pro Ser Thr Thr Ala Ala Arg Arg Ile Phe Tyr Asp Cys Thr 
100 105 110 
Asp Val Ala Phe Ser Pro Tyr Gly Glu Tyr Trp Arg Gln Val Arg Lys 
115 120 125 
Ile Cys Val Leu Glu Leu Leu Ser Ile Lys Arg Val Asn Ser Tyr Arg 
130 135 140 
Ser Ile Arg Glu Glu Glu Val Gly Leu Met Met Glu Arg Ile Ser Gln 
145 150 155 160 
Ser Cys Ser Thr Gly Glu Ala Val Asn Leu Ser Glu Leu Leu Leu Leu 
165 170 175 
Leu Ser Ser Gly Thr Ile Thr Arg Val Ala Phe Gly Lys Lys Tyr Glu 
180 185 190 
Gly Glu Glu Glu Arg Lys Asn Lys Phe Ala Asp Leu Ala Thr Glu Leu 
195 200 205 
Thr Thr Leu Met Gly Ala Phe Phe Val Gly Asp Tyr Phe Pro Ser Phe 
210 215 220 
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-continued 
Ala Trp Val Asp Val Leu Thr Gly Met Asp Ala Arg Leu Lys Arg Asn 
225 230 235 240 
His Gly Glu Leu Asp Ala Phe Val Asp His Val Ile Asp Asp His Leu 
245 250 255 
Leu Ser Arg Lys Ala Asn Gly Ser Asp Gly Val Glu Gln Lys Asp Leu 
260 265 270 
Val Asp Val Leu Leu His Leu Gln Lys Asp Ser Ser Leu Gly Val His 
275 280 285 
Leu Asn Arg Asn Asn Leu Lys Ala Val Ile Leu Asp Met Phe Ser Gly 
290 295 300 
Gly Thr Asp Thr Thr Ala Val Thr Leu Glu Trp Ala Met Ala Glu Leu 
305 310 315 320 
Ile Lys His Pro Asp Val Met Glu Lys Ala Gln Gln Glu Val Arg Arg 
325 330 335 
Val Val Gly Lys Lys Ala Lys Val Glu Glu Glu Asp Leu His Gln Leu 
340 345 350 
His Tyr Leu Lys Leu Ile Ile Lys Glu Thr Leu Arg Leu His Pro Val 
355 360 365 
Ala Pro Leu Leu Val Pro Arg Glu Ser Thr Arg Asp Val Val Ile Arg 
370 375 380 
Gly Tyr His Ile Pro Ala Lys Thr Arg Val Phe Ile Asn Ala Trp Ala 
385 390 395 400 
Ile Gly Arg Asp Pro Lys Ser Trp Glu Asn Ala Glu Glu Phe Leu Pro 
405 410 415 
Glu Arg Phe Val Asn Asn Ser Val Asp Phe Lys Gly Gln Asp Phe Gln 
420 425 430 
Leu Ile Pro Phe Gly Ala Gly Arg Arg Gly Cys Pro Gly Ile Ala Phe 
435 440 445 
Gly Ile Ser Ser Val Glu Ile Ser Leu Ala Asn Leu Leu Tyr Trp Phe 
450 455 460 
Asn Trp Glu Leu Pro Gly Ile 
465 470 
<210> SEQ ID NO 43 
<211> LENGTH, 509 
<212> TYPE, PRT 
<213> ORGANISM, Arabidopsis thaliana 
<400> SEQUENCE, 43 
Met Ala Phe Phe Ser Met Ile Ser Ile Leu Leu Gly Phe Val Ile Ser 
1 5 10 15 
Ser Phe Ile Phe Ile Phe Phe Phe Lys Lys Leu Leu Ser Phe Ser Arg 
20 25 30 
Lys Asn Met Ser Glu Val Ser Thr Leu Pro Ser Val Pro Val Val Pro 
35 40 45 
Gly Phe Pro Val Ile Gly Asn Leu Leu Gln Leu Lys Glu Lys Lys Pro 
50 55 60 
His Lys Thr Phe Thr Arg Trp Ser Glu Ile Tyr Gly Pro Ile Tyr Ser 
65 70 75 80 
Ile Lys Met Gly Ser Ser Ser Leu Ile Val Leu Asn Ser Thr Glu Thr 
85 90 95 
Ala Lys Glu Ala Met Val Thr Arg Phe Ser Ser Ile Ser Thr Arg Lys 
100 105 110 
Leu Ser Asn Ala Leu Thr Val Leu Thr Cys Asp Lys Ser Met Val Ala 
115 120 125 
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-continued 
Thr Ser Asp Tyr Asp Asp Phe His Lys Leu Val Lys Arg Cys Leu Leu 
130 135 140 
Asn Gly Leu Leu Gly Ala Asn Ala Gln Lys Arg Lys Arg His Tyr Arg 
145 150 155 160 
Asp Ala Leu Ile Glu Asn Val Ser Ser Lys Leu His Ala His Ala Arg 
165 170 175 
Asp His Pro Gln Glu Pro Val Asn Phe Arg Ala Ile Phe Glu His Glu 
180 185 190 
Leu Phe Gly Val Ala Leu Lys Gln Ala Phe Gly Lys Asp Val Glu Ser 
195 200 205 
Ile Tyr Val Lys Glu Leu Gly Val Thr Leu Ser Lys Asp Glu Ile Phe 
210 215 220 
Lys Val Leu Val His Asp Met Met Glu Gly Ala Ile Asp Val Asp Trp 
225 230 235 240 
Arg Asp Phe Phe Pro Tyr Leu Lys Trp Ile Pro Asn Lys Ser Phe Glu 
245 250 255 
Ala Arg Ile Gln Gln Lys His Lys Arg Arg Leu Ala Val Met Asn Ala 
260 265 270 
Leu Ile Gln Asp Arg Leu Lys Gln Asn Gly Ser Glu Ser Asp Asp Asp 
275 280 285 
Cys Tyr Leu Asn Phe Leu Met Ser Glu Ala Lys Thr Leu Thr Lys Glu 
290 295 300 
Gln Ile Ala Ile Leu Val Trp Glu Thr Ile Ile Glu Thr Ala Asp Thr 
305 310 315 320 
Thr Leu Val Thr Thr Glu Trp Ala Ile Tyr Glu Leu Ala Lys His Pro 
325 330 335 
Ser Val Gln Asp Arg Leu Cys Lys Glu Ile Gln Asn Val Cys Gly Gly 
340 345 350 
Glu Lys Phe Lys Glu Glu Gln Leu Ser Gln Val Pro Tyr Leu Asn Gly 
355 360 365 
Val Phe His Glu Thr Leu Arg Lys Tyr Ser Pro Ala Pro Leu Val Pro 
370 375 380 
Ile Arg Tyr Ala His Glu Asp Thr Gln Ile Gly Gly Tyr His Val Pro 
385 390 395 400 
Ala Gly Ser Glu Ile Ala Ile Asn Ile Tyr Gly Cys Asn Met Asp Lys 
405 410 415 
Lys Arg Trp Glu Arg Pro Glu Asp Trp Trp Pro Glu Arg Phe Leu Asp 
420 425 430 
Asp Gly Lys Tyr Glu Thr Ser Asp Leu His Lys Thr Met Ala Phe Gly 
435 440 445 
Ala Gly Lys Arg Val Cys Ala Gly Ala Leu Gln Ala Ser Leu Met Ala 
450 455 460 
Gly Ile Ala Ile Gly Arg Leu Val Gln Glu Phe Glu Trp Lys Leu Arg 
465 470 475 480 
Asp Gly Glu Glu Glu Asn Val Asp Thr Tyr Gly Leu Thr Ser Gln Lys 
485 490 495 
Leu Tyr Pro Leu Met Ala Ile Ile Asn Pro Arg Arg Ser 
500 505 
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The invention claimed is: 
1. A method for producing in a recombinant host cell an 
isoprenoid compound not endogenously produced by a non 
recombinant host cell, comprising: 65 
a) providing a recombinant host cell that comprises het-
erologous nucleic acid encoding an isoprenoid syn-
thase, and heterologous nucleic acid encoding one or 
more protein(s) comprising a CYP71, CYP73, CYP82 
or a CYP92 family cytochrome P450 polypeptide 
encoded by nucleic acid that can be amplified with 
degenerate primers based on any one of SEQ ID NOs: 
26-29, wherein: 
US 10,184,118 B2 
75 
the isoprenoid synthase catalyzes production of an 
isoprenoid compound; 
wherein the isoprenoid synthase is a sesquiterpene 
synthase; and 
the cytochrome P450 polypeptide(s) catalyzes dual 5 
hydroxylation, oxidation, demethylation or methyl-
ation of the isoprenoid compound; and 
b) culturing the recombinant host cell under conditions 
suitable for expressing the isoprenoid synthase and 
the cytochrome P450 polypeptide(s) under condi- 10 
tions for producing the isoprenoid compound 
wherein the synthase and the cytochrome P450 poly-
peptide(s) catalyze formation of the isoprenoid com-
pound in the host cell. 
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acid that can be amplified with degenerate primers based on 
any one of SEQ ID NOs: 26-29, wherein: 
the nucleic acid encoding the synthase and the nucleic 
acid encoding the P450 polypeptides are heterologous 
to the host cell; 
the synthase catalyzes production of an isoprenoid com-
pound; 
the isoprenoid synthase is a sesquiterpene synthase; 
the P450 polypeptides catalyze hydroxylation, oxidation, 
demethylation or methylation of the isoprenoid com-
pound; 
at least one of the P450 polypeptide(s) catalyzes the dual 
hydroxylation, oxidation, demethylation or methyl-
ation of the isoprenoid compound whose production is 
catalyzed by the synthase; and 
2. The method of claim 1, wherein at least one 15 
cytochrome P450 polypeptide has oxidase activity. 
the isoprenoid compound produced by the host cell is not 
endogenously produced by a non recombinant host cell. 
11. ~e host cell of claim 10 that is a yeast cell, a bacterial 
20 cell, an msect cell or a plant cell. 
3. The method of claim 1, wherein at least one 
cytochrome P450 polypeptide has dual hydroxylase activity. 
4. The method of claim 1, wherein the host cell is a yeast 
cell, a bacterial cell, an insect cell or a plant cell. 
12. The host cell of claim 10 that is a yeast cell. 5. The method of claim 1, wherein the host cell is a yeast 
cell. 
6. The method of claim 5, wherein the yeast is Saccha-
romyces cerevisiae. 
7. The method of claim 1, wherein at least one of the 25 
cytochrome P450 polypeptides is 5-epi-aristolochene 
hydroxylase or kaurene oxidase. 
8. The method of claim 1, wherein the isoprenoid com-
pound is a sesquiterpene. 
9. The method of claim 1, further comprising c) isolating 30 
the isoprenoid compound. 
. 10. A_ host cell, comprising nucleic acid encoding an 
1sopren01d synthase and nucleic acid encoding one or more 
protein(s) comprising a CYP71, CYP73, CYP82 or a CYP92 
family cytochrome P450 polypeptides encoded by nucleic 
13. The host cell of claim 10, wherein at least one of the 
cytochrome P450 polypeptide(s) is 5-epi-aristolochene 
hydroxylase or kaurene oxidase. 
14. The method of claim 1, wherein at least one of the 
cytochrome P450polypeptide(s) is selected from among 
polypeptides comprising at least 80% identity to an amino 
acid sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID 
NO: 5, SEQ ID NO: 7, SEQ ID NO: 9and SEQ ID N0:11. 
15. The host cell of claim 10, wherein at least one of the 
cytochrome P450polypeptide(s) is selected from among 
polypeptides comprising at least 80 % identity to an amino 
acid sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID 
NO: 5, SEQ ID NO: 7, SEQ ID NO: 9 and SEQ ID N0:11. 
* * * * * 
